

Ö ...²Áõ¥>f

j 5 0Y □ 0Y L h0Y L

1

1

j 6 5eÂqñ...5 SYd 7 P M V N F / V N C F S . B S D I



┘ ä ┘ y ɾ ɤ

˘E y ˘E ʒ ʋ y ˘E ʒ ʋ ˘E

ʒ ʋ ┘ ʒ

/ 7 5 56 ʘ 0 . . / Δ ɤ ┘

ɤ 0 . . 4 ≡ ┘ ≡ ┘

ɔ æ y ┘ ɤ ʒ

0 . / ʒ ← ɤ || ɤ ┘ y ||^m 0 . / ʒ

┘ ʘ ε y ┘ ʘ^m ʒ

ʒ ʋ ɔ Ĩ ɾ y ┘ í ɔ ʘ / 7 ʒ • ɤ

Ê Ȳ í ˘ ˘ ɔ ɤ y • ʘ ʘ ʒ

˘ y ʒ ɤ ♥ ɤ ʔ ʔ ɐ

♥ y ɤ ʔ í ˘

ʘ ɔ ʔ ʒ

ɤ / . m ʘ ʒ ˘ ┘ 0

► ɤ ʔ / ʒ ʋ ┘ || ɤ ┘ ┘ ʔ ɤ^m ɤ ɤ

ɤ ʒ ┘ ɤ ʘ Δ ɤ ɤ^m ɤ ʒ ┘ ɤ ɾ y ┘ ʔ ɤ

˘ ɤ ɤ y ɤ ʒ ɾ ɤ || ɤ • ʘ Δ ʘ ɤ

ɤ^m ɤ ɤ ɤ ┘ ˘ ┘ ɾ ɤ ʘ ʘ ʒ ┘ ||

ɤ y ʘ Δ ɤ ɤ ʒ ɤ ┘ í ʔ ɔ ʘ

┘ ┘ ɤ y ʔ ɤ ʒ ɤ ɤ ɤ ┘ ┘ ɤ ʔ ɤ^m

ɤ ɤ ɤ ʒ

分子诊断与治疗杂志

Ëþ' Írr~7'*òrr ÷' Èrtû—' Ñrt w' Úrqz×' \rtPþ' j \$ Ó • □ \$ Ó ZrpÀ'S' È »rq:Ç'l~lÞrrÂrp"€0vU• UŽ ÝrpËþ' Írr~7'*òrr ñô ™—

[illegible]

JOURNAL OF MOLECULAR DIAGNOSTICS AND THERAPY

Monthly Volume 12 Number 2 March 2020

CONTENTS

COMMENTS

JOURNAL OF MOLECULAR DIAGNOSTICS AND THERAPY

Monthly Volume 12 Number 3 March 2020

CONTENTS

Experimental study of miR-21 promotes the proliferation of prostate cancer cell line DU 123 by targeting PDCD2 LI Zuowei GUO Hang DENG Chao YAN Dongliang TIAN Binqiang	332
Serum IL-17, IL-6 and IFN- γ in the qualitative diagnosis of breast tumors and their correlation with prognosis GUO Qi YAO Chang GUO Yufei	336
Relationship between CD3 ⁺ HLA-DR cells and immune disorders and ovarian function in patients with early onset ovarian insufficiency GUO Mitian ZHANG Ji WANG Sumei	340
Study on the relationship between immune function imbalance and disease activity in patients with rheumatoid arthritis MENG Qingfang	345
Effects of CysC, Hcy, MP, NT-proBNP on restenosis after STEMI ZOU Yanxin LI Ni Ni ZHANG Yuehua ZHANG Xiuzhen	349
Evaluation of serum β -HCG, progesterone and vaginal ultrasound in the diagnosis and treatment of unruptured ectopic pregnancy YAN Xueping TIAN Yuan WU Qingjing	353
Clinical Significance of Serum MMP-9, IFN- γ and HMGB-1, TLR-4 mRNA in Lupus Nephritis LU Bing REN Dongsheng TAO Yafei LI Ming	358
Correlation between detection of Angptl-4, CTLA-4 and vitamin D and coagulation function in patients with membranous nephropathy JIA Limin ZHAO Cui WEI Di FANG Xiaofang	362
The predictive value of serum BUN	

Z ǃ 0 . / 5 2 1 1
 ǃ ǃ / , ǃ ǃ ǃ ǃ 3 / / 2 . .
 0 , ǃ ǃ ǃ ǃ 3 / / 2 . .
 ǃ ǃ C g k _ j _ j w / 7 5 5 1 , a m k C g k _ a _ j _ / 0 4 > a m k
 ǃ ǃ ǃ ǃ ǃ ǃ C g C ǃ ǃ C g _ ǃ C g 0 0 A

ò Ò» Ywà Þ}U' h>n Ù ý0?ó

$\leftarrow \mathbb{W}$ $\mathbb{O}$ $\varnothing$ $\mathbb{O}$ $\mathbb{I}$ $\varnothing$
 $\mathbb{O}$ $\tilde{\omega}$ $0. / 5 \times 11.00. /$
 $\Theta \quad \pi \mathbb{H}$ $/ \leftarrow \mathbb{W}$ $\mathbb{I}$ $\mathbb{O}$ Ψ $\leftarrow \mathbb{W} / . . / 7 /$
 $0 \leftarrow \mathbb{W}$ $\mathbb{K}$ $\mathbb{I}$ $\leftarrow \mathbb{W} / . . . 22$
 $\rho \quad m \Theta$ i $C g k j \varnothing j, d c l e k g l > f q a, n i s, c b s, a l$

AR

Q ? P Q U A m T U

/ Ω 0p 1 Ω 1 0 1 h 0 K W 1 A A M T = U / 7 G

Я

Q ? P Q U A m T U Ğ w e d j =
w P R U N A P Q ? P Q U A m T U _ 4 L Ğ ũ 0 ħ Q ? P Q U A m T U í w d
j ~ 1 ħ A M T G / B U 0 ħ U 4 2 1 / 7 2 P 0 2 d ж 4 - 3 ħ v / ↓
ħ / ħ / ħ j _ 0 ħ Q ? P Q U A m T U Ğ U ħ
H ~ L Ğ . 1 ~ j _ 0 ħ A M T G / B U 1 . , 4 ħ .
AR j A d Ğ j _ n H w 1 / 1 / 2 1 ; ~ ~
/ // 2 Ĩ // 2 2 . ħ Ÿ / / - / 2

0 . / 7 1 H W D
Θ π H / , ► ж | d Z 0 4 2 0 . .
0 , ж | ψ \$ í ũ ψ Ğ | ũ
í | ψ Z 0 5 4 6 0 4
1 , Ğ ψ Z 0 5 4 6 0 4
° n Θ Ω C g k _ u g e j n p 7 1 1 0 4 , a m k

P<...5 т ↓

2

2.1 і

6556 ж 23 з SARS Co T 2
5 | 63 13Б1.
‘ е Ψ 3 з 13..%
COTID19 2. з 65..% ↓ COTID19
2. з Ψ п 2. з І 35.3Ÿ β9Ÿ Ј Ѱ 14
з 5 з і Ω 9 з 2 з Ј Ў 2 | 24
5 з ж 5 з ѱ 1 з
1 з 13 з ε 1
• ↓

2.2 SARS Co T 2

SARS Co T 2 23 з ‘ 4
‘А ‘ ORF1a/b dN Ė ‘H 0o † ŒXĐ p , !
І IPC 1 в † Ѱ с S1 H
e І † ↓ 23 з
ˆ в в SARS Co T 9 CT
2 ORF1a/b dN Ė
1 Hь ˆ ORF1a/b dN Ė
6 | 35 N Ė 1 ˆ
CT 19 з 9
↓

2.3 COTID19

23 з SARS Co T 2 d ‘A CT 9 з
39. CT

! ,4'''94\$@9

\$ 5 :D 0 d \$ 5Y eF \$ E 6 % eY B æ e nV" 3 \$!P m e&¥ B í L " r0tE— — ! ÿ• ! ÿ•0—" —

r
 1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 52

BGLE Vq_mw_l I C XfgwgXFS VgswsIXFCLE F_gvq_WS?L HgIe N?L W_laf_m XF?LE Kglevq
RfcRfgpbncmniBq Fmgqr j md Qfclxfcl Glgrgrsrc md Fcn rmimEfcclxfcl Es lebmle Afql 3/6//0

?@QRP?AR M'hcargtc Rm am kn_pc_l_b_l_jwxc rfc brcargml pcqsjrj md bgddpcplr lmtcj ampm_l_tgpsq Q?PQUAmTQ lsaicga_agb brcargml pc_eclrq dmp pcdpcplac gl rfc j`mp\_rmp\_krcrfmbq ? rmr\_j md ./ pck\_glg le lsaicga\_agb\_q knjcg ucpc amjjcarb dmp ajjlgaj rcqr gl msp fmqrj ml Dc`p3_pwb // _lb rum bmkcrga igrq ucpc sqcb dmp n_p_jjc rcqr gl rm ncpdmpk lsaicga_agb_knjgdga_rgm l, Rfc ncpdmpk_lac md rfc q_knjcg u_q am kn_pcb_aampbgl rm rfc rcqr pcqsjrj md c_af pc_eclrq ? kmle rfc ./ q_knjcg 10 ucpc nmqgrtc dmp pc_eclr ? nmqgrtc p_rc1 / , 46 #34 ucpc lce_rgtc lce_rgtc p_rc33 , 23 # 13 ucpc nmqgrtc dmp pc_eclr @ nmqgrtc p_rc12 , 43 # _lb 31 ucpc lce_rgtc lce_rgtc p_rc30 , 26 #, Rfc bgddpcplac u_q lmr qr_rqrga_jjw qgelgdga_lr =.2169 P=.6952 . According to the single channel results of the kit the detection rate of the N detection site of the two kits was higher than that of ORF1a/b the detection rates of two channels of reagent A were ORF1ab 31.66% N 44.55% respectively. Reagent B were ORF1a/B 35.64% N 4.59%. The detection results of the N detection site of the two kits were r kio 9thethe N th P Ô Ð 3 65t> s*

	с ж		с ~	г	QXOK / 3 / 0 . . 3
Θ π Η	с ж			Z	3 / 6 / / 0
ρ м θ	C g k x d j v k		` w >	m s r j m m i , a m k	

$P < \dots 5 \varepsilon$

$\tau \downarrow$

2

2.1

Ξ

'H

$\tilde{Y}$

Ξ

'H

f

PCR

w

'Y

ε

N

ε

N

ε

N

ε

N

ε

N

1

N

ε

N

ε

N

ε

N

ε

N

ε

N

ε

N

ε

N

ε

N

ε

N

ε

N

ε

copies/mL

ε

N

ε

N

ε

N

ε

N

ε

N

ε

mL

ε

N

ε

N

ε

N

ε

N

ε

N

ε

1

ε

N

ε

N

ε

N

ε

N

ε

N

τ

Ξ

'H

μ

$\tilde{I}$

$\downarrow$

1

$\downarrow$

2.2

Ξ

'H

μ

$\tilde{I}$

$\downarrow$

1

$\downarrow$

'H

μ

$\tilde{I}$

$\downarrow$

1

$\downarrow$

'H

μ

$\tilde{I}$

$\downarrow$

1

$\downarrow$


$\circ$

π Υ ξ ο
 @A7AQ524'u W(1/4(`

Table 3 Single channel detection rate analysis of 2 reagents

	A n=1.1						B n=1.1					
ORF1a/b	32	31.66	56	55.45	13	12.65	36	35.64	56	55.43	5	6.93
N	45	44.55	52	51.49	4	3.96	41	4.59	56	55.45	4	3.96

Table 4 Ct values of 14 positive samples							
ORF1a/b		B					
ORF1a/b	N	ORF1a/b	N				
26.55	23.52	23.15	24.22				
31.25	26.12	25.52	26.21				
34.24	32.51	31.55	32.95				
34.92	33.23	33.15	33.29				
36.54	34.69	34.95	34.93				
32.12	29.61	29.61	31.11				
26.45	25.11	25.34	26.11				
23.52	21.94	21.64	21.61				
35.12	33.35	31.65	32.13				
34.16	31.65	31.45	31.66				
34.39	33.12	32.16	32.99				
26.62	26.54	26.11	25.45				
35.15	33.51	33.51	33.91				
36.61	35.25	36.59	35.12				
n nose		t throat		s sputum			



54564.5.htm

Figure 2 The results of 14 positive samples tested by 2 reagents

Nucleocapsid N Spike S
 Membrane M
 qPCR
 RNA 2.19 nCo T
 1a/b
 2.19 nCo T ORF1a/b
 1.1
 12.65%
 12.65%
 12.65%

Иб ρ ρ

а І 'Н Ә Ъ 4 ѿ Δ Ā / 6 'Н

Ө Ψ Ğ Ъ 'Н Ј ѿ Δ ѿ ѿ У т 'А У т

ѳ ѿ Δ Ъ т а Ъ т 'А ө ө І 2Y

ѳ WW - R3 ѿ 5. nU5rU Ψ Ğ Ů 'Н ѱ Δ 'А ѳ м Ψ

а Ъ т 'А ө І 1Y Ј / 6 'Н

ѳ ѿ У т 'А У т ѿ 'А Δ 'А ѿ ѿ Δ У т 'А У т

Ј ѿ Δ 'А ѳ м а Ъ т / 'Н

ѳ ѿ Δ 'А ө 'Н ѳ Ј ѿ Δ ѱ Δ

'А ѿ ѿ ѿ ѿ У т м ѳ а Ъ т ѳ 'Н

ө Ė ' Ј

Ā Ψ Ů ă Ъ ă

Os_jgrw_l_jwqgq md rf_j_qqckg_eclc bcrcargml_igr q_knjgle

XF?LE UclvgIWS Rgle QSL L_I E?M Dcg FS?LE Hgc OS Qfmsd_lē

Bgtqgml md Gl Tgrpm Bg_elmqrga dmp Lml U Gldcargmsq Bggc_qcqlqrgsrc dmp Gl Tgrpm Bg_elmqrgaq AmIrpmj
L_rgmI_j Glqrgsrcq dmp Dmmb_lb Bpse AmIrpm@cghgle AfgI_ /...3.

?@QRP?AR M`hcargtc ?aampbgle rm rfc L_rgmI_j Gl tgrpm Bg_elmqrgaGTB Pc_eclr Q_knjgle
Umpi Nmpem_k_rmr_j md / 6`_rafcq md igrq ucpc q_knjcb dpmk4 amkn_lgcq rm ct_js_rc rfc os_jgrw md
rf_j_qqckg_eclc ksr_rgmI bcrcargml igrqKcrfmbq Rfc_aasp_aw qncagdgagr w jgkgr md bcrcargml_lb
pcnc_r`ggrw ucpc tcpgdgcb gl\_aampb\_lac ugrf rfc npmbasar rcaflga\_j pcosgpccklrq`w sqgle rfc clrcpnpgqc

C M S P V C r p B S B P A B C X C @ D S R V J S F B F B U P O d R P @ @ O W D V G F • T F • Z P 0 1ōwP6 Y


ф ѿ ѿ 0 . / 4WDA . 1 . .

Ө П Н Ψ а т т І 'Н К 'Н ѿ ѿ / . . . 3 .

ρ н ө C g k h g j s 3_l e 0 0 4 , a m k C g k o g j f m s / 0_4 l, a m k

І Н ε "Ω м ө І ε "Ω н ө





[illegible]

Cqr_`jgqf kclr md\_ lcu kcrfmb dmp brcargle kcrfgagjjgl Îpcqqr\_Îr Staphylococcus aureus `w NAP

VGLE Kcg DS Jg Ijg I^p

Bcn_prkclr md J_`mp_rmpw KcbgagldUclaf_le Eclcp_j Fmqngr_jUclaf_le F_gl_l Afgl_ 35/10/

Staphylococcus aureus strains. Methods Pathogenic bacteria strains were isolated and cultured from pus secretions, blood and other specimens of severe patients admitted to ICU of our hospital from January 2016 to December 2016. A total of 43 samples were collected. All strains originated from different patients and were obtained from initial isolation. Samples were detected by real time fluorescence PCR and disk diffusion methods respectively. Results The accuracy of real time fluorescence PCR method was higher than that of cefoxitin and oxacillin disk diffusion method. All methicillin resistant staphylococci are resistant to oxacillin and penicillin and more resistant to erythromycin and clindamycin. They are sensitive to vancomycin, linezolid, tigecycline, rifampicin, tetracycline, gentamicin. Conclusion Compared with cefoxitin and oxacillin disk diffusion methods, the newly established fluorescent PCR method not only has high accuracy, but also has good specificity and can accurately detect methicillin resistant *Staphylococcus aureus*.

KEW WORDS PCR Methicillin resistant *Staphylococcus aureus* *mecA* gene Cefoxitin Cefoxitin
disk diffusion method

Staphylococcus aureus SA 3

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Table 3 Test results of methicillin resistant Staphylococcus aureus in methicillin resistant strain samples

	"H j	r	U	mecA	NUC
		K B	K B	ğ	ğ
1	-	>25	>12	)	-
2	-	<25	>12	)	-
3	)	>25	>12	)	)
4	-	>25	>12	)	-
5	-	>25	<12	)	-
6	-	>25	<12	)	-
5	-	<25	>12	)	-
6	)	>25	>12	)	)
9	-	>25	>12	)	-
1.	-	>25	<12	)	-
11	-	>25	<12	)	-

Table 2 Comparison of real time fluorescent PCR method and paper diffusion method to detect mecA gene

	3	3
w PCR	11	32
r K B	5	36
U K B	6	35




Figure 1 Results of real time fluorescent PCR detection of mecA gene in the sample

2.2

11 3 mecA 5
 NUC 5 2 3 c 5
 mecA 5 3 5 NUC 5 5 5
 1 3 2 1

2.3

w mecA ٤ ٧ ١٤ ٢٨ ٤٠ ٥٦ ٧٢ ٨٨ ١١٢ ١٤٠ ١٦٨ ٢٠٠ ٢٢٤ ٢٤٨ ٢٧٢ ٢٩٦ ٣٢٠ ٣٤٤ ٣٦٨ ٣٩٢ ٤١٦ ٤٤٠ ٤٦٤ ٤٨٨ ٥١٢ ٥٣٦ ٥٦٠ ٥٨٤ ٦٠٨ ٦٣٢ ٦٥٦ ٦٨٠ ٧٠٤ ٧٢٨ ٧٥٢ ٧٧٦ ٨٠٠ ٨٢٤ ٨٤٨ ٨٧٢ ٨٩٦ ٩٢٠ ٩٤٤ ٩٦٨ ٩٩٢ ١٠١٦ ١٠٤٠ ١٠٦٤ ١٠٨٨ ١١١٢ ١١٣٦ ١١٦٠ ١١٨٤ ١٢٠٨ ١٢٣٢ ١٢٥٦ ١٢٨٠ ١٣٠٤ ١٣٢٨ ١٣٥٢ ١٣٧٦ ١٤٠٠ ١٤٢٤ ١٤٤٨ ١٤٧٢ ١٤٩٦ ١٥٢٠ ١٥٤٤ ١٥٦٨ ١٥٩٢ ١٦١٦ ١٦٤٠ ١٦٦٤ ١٦٨٨ ١٧١٢ ١٧٣٦ ١٧٦٠ ١٧٨٤ ١٨٠٨ ١٨٣٢ ١٨٥٦ ١٨٨٠ ١٩٠٤ ١٩٢٨ ١٩٥٢ ١٩٧٦ ٢٠٠٠ ٢٠٢٤ ٢٠٤٨ ٢٠٧٢ ٢٠٩٦ ٢١٢٠ ٢١٤٤ ٢١٦٨ ٢١٩٢ ٢٢١٦ ٢٢٤٠ ٢٢٦٤ ٢٢٨٨ ٢٣١٢ ٢٣٣٦ ٢٣٦٠ ٢٣٨٤ ٢٤٠٨ ٢٤٣٢ ٢٤٥٦ ٢٤٨٠ ٢٥٠٤ ٢٥٢٨ ٢٥٥٢ ٢٥٧٦ ٢٦٠٠ ٢٦٢٤ ٢٦٤٨ ٢٦٧٢ ٢٦٩٦ ٢٧٢٠ ٢٧٤٤ ٢٧٦٨ ٢٧٩٢ ٢٨١٦ ٢٨٤٠ ٢٨٦٤ ٢٨٨٨ ٢٩١٢ ٢٩٣٦ ٢٩٦٠ ٢٩٨٤ ٣٠٠٨ ٣٠٣٢ ٣٠٥٦ ٣٠٨٠ ٣١٠٤ ٣١٢٨ ٣١٥٢ ٣١٧٦ ٣٢٠٠ ٣٢٢٤ ٣٢٤٨ ٣٢٧٢ ٣٢٩٦ ٣٣٢٠ ٣٣٤٤ ٣٣٦٨ ٣٣٩٢ ٣٤١٦ ٣٤٤٠ ٣٤٦٤ ٣٤٨٨ ٣٥١٢ ٣٥٣٦ ٣٥٦٠ ٣٥٨٤ ٣٦٠٨ ٣٦٣٢ ٣٦٥٦ ٣٦٨٠ ٣٧٠٤ ٣٧٢٨ ٣٧٥٢ ٣٧٧٦ ٣٨٠٠ ٣٨٢٤ ٣٨٤٨ ٣٨٧٢ ٣٨٩٦ ٣٩٢٠ ٣٩٤٤ ٣٩٦٨ ٣٩٩٢ ٤٠١٦ ٤٠٤٠ ٤٠٦٤ ٤٠٨٨ ٤١١٢ ٤١٣٦ ٤١٦٠ ٤١٨٤ ٤٢٠٨ ٤٢٣٢ ٤٢٥٦ ٤٢٨٠ ٤٣٠٤ ٤٣٢٨ ٤٣٥٢ ٤٣٧٦ ٤٤٠٠ ٤٤٢٤ ٤٤٤٨ ٤٤٧٢ ٤٤٩٦ ٤٥٢٠ ٤٥٤٤ ٤٥٦٨ ٤٥٩٢ ٤٦١٦ ٤٦٤٠ ٤٦٦٤ ٤٦٨٨ ٤٧١٢ ٤٧٣٦ ٤٧٦٠ ٤٧٨٤ ٤٨٠٨ ٤٨٣٢ ٤٨٥٦ ٤٨٨٠ ٤٩٠٤ ٤٩٢٨ ٤٩٥٢ ٤٩٧٦ ٥٠٠٠ ٥٠٢٤ ٥٠٤٨ ٥٠٧٢ ٥٠٩٦ ٥١٢٠ ٥١٤٤ ٥١٦٨ ٥١٩٢ ٥٢١٦ ٥٢٤٠ ٥٢٦٤ ٥٢٨٨ ٥٣١٢ ٥٣٣٦ ٥٣٦٠ ٥٣٨٤ ٥٤٠٨ ٥٤٣٢ ٥٤٥٦ ٥٤٨٠ ٥٥٠٤ ٥٥٢٨ ٥٥٥٢ ٥٥٧٦ ٥٦٠٠ ٥٦٢٤ ٥٦٤٨ ٥٦٧٢ ٥٦٩٦ ٥٧٢٠ ٥٧٤٤ ٥٧٦٨ ٥٧٩٢ ٥٨١٦ ٥٨٤٠ ٥٨٦٤ ٥٨٨٨ ٥٩١٢ ٥٩٣٦ ٥٩٦٠ ٥٩٨٤ ٦٠٠٨ ٦٠٣٢ ٦٠٥٦ ٦٠٨٠ ٦١٠٤ ٦١٢٨ ٦١٥٢ ٦١٧٦ ٦٢٠٠ ٦٢٢٤ ٦٢٤٨ ٦٢٧٢ ٦٢٩٦ ٦٣٢٠ ٦٣٤٤ ٦٣٦٨ ٦٣٩٢ ٦٤١٦ ٦٤٤٠ ٦٤٦٤ ٦٤٨٨ ٦٥١٢ ٦٥٣٦ ٦٥٦٠ ٦٥٨٤ ٦٦٠٨ ٦٦٣٢ ٦٦٥٦ ٦٦٨٠ ٦٧٠٤ ٦٧٢٨ ٦٧٥٢ ٦٧٧٦ ٦٨٠٠ ٦٨٢٤ ٦٨٤٨ ٦٨٧٢ ٦٨٩٦ ٦٩٢٠ ٦٩٤٤ ٦٩٦٨ ٦٩٩٢ ٧٠١٦ ٧٠٤٠ ٧٠٦٤ ٧٠٨٨ ٧١١٢ ٧١٣٦ ٧١٦٠ ٧١٨٤ ٧٢٠٨ ٧٢٣٢ ٧٢٥٦ ٧٢٨٠ ٧٣٠٤ ٧٣٢٨ ٧٣٥٢ ٧٣٧٦ ٧٤٠٠ ٧٤٢٤ ٧٤٤٨ ٧٤٧٢ ٧٤٩٦ ٧٥٢٠ ٧٥٤٤ ٧٥٦٨ ٧٥٩٢ ٧٦١٦ ٧٦٤٠ ٧٦٦٤ ٧٦٨٨ ٧٧١٢ ٧٧٣٦ ٧٧٦٠ ٧٧٨٤ ٧٨٠٨ ٧٨٣٢ ٧٨٥٦ ٧٨٨٠ ٧٩٠٤ ٧٩٢٨ ٧٩٥٢ ٧٩٧٦ ٨٠٠٠ ٨٠٢٤ ٨٠٤٨ ٨٠٧٢ ٨٠٩٦ ٨١٢٠ ٨١٤٤ ٨١٦٨ ٨١٩٢ ٨٢١٦ ٨٢٤٠ ٨٢٦٤ ٨٢٨٨ ٨٣١٢ ٨٣٣٦ ٨٣٦٠ ٨٣٨٤ ٨٤٠٨ ٨٤٣٢ ٨٤٥٦ ٨٤٨٠ ٨٥٠٤ ٨٥٢٨ ٨٥٥٢ ٨٥٧٦ ٨٦٠٠ ٨٦٢٤ ٨٦٤٨ ٨٦٧٢ ٨٦٩٦ ٨٧٢٠ ٨٧٤٤ ٨٧٦٨ ٨٧٩٢ ٨٨١٦ ٨٨٤٠ ٨٨٦٤ ٨٨٨٨ ٨٩١٢ ٨٩٣٦ ٨٩٦٠ ٨٩٨٤ ٩٠٠٨ ٩٠٣٢ ٩٠٥٦ ٩٠٨٠

3

† 6 6 6 x 6

16

↓

Y A α MRSA B c mecA E t Dd d

SPB15 Y H O 1 Ω

↓ K

w
 u ĩ
 mecA ↓
 Ψ κ I I κ Θ ̃ y ↓ 'Y
 23 24
 w PCR Ψ
 w PCR ' w PCR κ Ψ
 w n ~ 6 ' w
 ̃ O MRSA ̃ γ p 6

mecA ̃ H SA Y ̃
 Θ ' mecA Ж ̃ κ
 ̃ ̃ ̃ mecA
 ̃ ̃ ̃ ̃ 19 ↓
 ̃ mecA ̃ ' Θ ε MRSA
 m ̃ 2. ↓
 w 21 ' PBP2a H
 ̃ mecl mecA ̃ "A Θ ̃
 . f mecA ̃ U ↓
 Ψ ̃ f m ĩ "E ̃
 Ж ↓ Ψ w PCR
 ̃ H r ̃ U
 'Y I U
 'O I ̃
 Ψ H ̃ U 6
 ̃ ̃ ̃ ̃ ̃
 ̃ ̃ ̃ ̃ ̃
 ̃ ̃ ̃ ̃ ̃
 ' w 22 I ̃ w
 PCR K ̃ I ̃
 'Y Ψ f ̃ w PCR
 ̃ mecA ̃ I Taqman

TCEĐ p m Ÿ ? B K

ρ τ 0

٢ Ĩ Ğ TCEĐ ǫ n p m Ÿ ? B K ٧

٧ Ą T ? N O A ~ Ą ٥ . / 35 0 . / 65 ٧

Ψ <0 2 / ٣ 5 ٤ ε T ? ٧ O Ũ ٥ •

0 ٤ ٥Ψ • 1 ٣ ٧ • 0 ٣ í Ũ 3 5 ١ H / ٣

٣ C J G Q ? ~ TCEĐ n p m Ÿ ? B K ~ TCEĐ n p m Ÿ ? B K ٧ ٧ 3

φ Ą ٥ TCEĐ p m Ÿ ? B K T ? N O A ~ Ą ٥

T ? N TCEĐ ٥ n p m Ÿ ? B K T ? N ٣ P < ... 5 3 TEGF ٥ pro ADM

٥ • < Ψ • < • τ P < ... 5 ٥ Ą Ũ TAP Ψ

TEGF A pro ADM ٧ Ą r = .664 P = ... ٥ ROC Ũ TEGF ;

ACU .6.4 95%CI .552 | .656 ȳ ٥ 13.6 pg/mL ٣ 6 TAP ~ *

ε 62.9.% ٧ ε 53.5.% pro ADM ACU .546 95%CI .693 | .6.4 ȳ ٥ 3.12 nmol/L

٣ 6 TAP ~ * ε 93.5.% ٧ ε 66.6.% ٥ ٧ Ą

Ψ TEGF A pro ADM ٧ Ą TEGF pro ADM ٧

٥ ~ ' TEGFA pro ADM ٧ ' ٧ Ą

O ١ í ~ ٥ ٥ ٥

Ą Ĩ Ğ ǫ ٧ Ą ~

Pcj_rgmIqfgn `cruccl qcpsk TCED _Ib npmÎ?BK jctcjq _Ib rfc qctcpgrw _Ib
npmeImqqq md cjbcpjw n_rgcIrq ugrf tclrgj_rmpÎ_qqmaq_rcb nlcskmIq_

WSQSPFVA5DQ1CQpSE-6Q00@GE P&@'ÂTD X'J'U78(1,ÂS)P&COT7p16AAIOFX&UFA2)kJE"QPT 0 P V2Q0

α 1 / 6 . 0 . 0 2

Θ π Η / , f | c | ٧ ٧ Ĩ ± f 2 3 1 . . .

0 , f | ± f 2 3 1 . . .

ρ n Θ C g k _h ٥ _l m b m l / e4f1s, _almek>

ADM ¯ ¯ ¶ É P<
...5ϑYa ¯"1 7 &(' !a ! 7 &(' d 0
=•

x±s ≡ f t
f π Ē Ũ

P<...5 ε


τ ↓

2

2.1 ≡ í
TAP TEGFøpro ADM ψ
APACHE n Ũ Ъ TAP
τ P<...5 TAP
Ъ TAP τ P<...5
1 ↓

2.2 TAP Ψ TEGFøpro
ADM
3 TEGFøpro ADM ψ
Ъ Н • Ѡ • • TEGFøpro

5 Ж ј ' . f Ĩ 6
 H 1 ъ ц п
 Ğ Ψ m 13 14 ј Ä
 15 п њ њ Ä К 'O
 TEGF ĩ A ' S'O
 ĩ ј TAP O
 ' К 1 ~ Ÿ ј
 3 6 6ä ä ѡ
 H ♥ Ө Ě I Ө
 16 ј ж ę ǫ 3 ε 3
 ǫ I ę 6L 'Y
 ' К 3 ј
 ǫ Ψ í 3
 pro ADM τ pro ADM
 ѡ T 6 ~
 Ө e 15 ј 'A TAP TAP
 pro ADM τ ĩ 'Y ę
 pro ADM τ ĩ pro
 ADM S ' К O ј
 pro ADM 'A TAP í ~ п
 TAP H pro ADM τ
 ĩ ę ~ * Ÿ
 Ä ј TAP O '
 К 1 ~ Ÿ ј
 3 њ њ Ä Ψ
 ' TEGF 1 pro ADM τ ' ę



$r = .664$ $P = \dots$ ј

3

TAP Ψ m
 ę п ĩ
 f O 6 ј í 3
 ѡ TAP ж щ
 14% 4.% ę 1
 6.% 9 ј ǫ í 3 H TAP
 S Ё Ө ε t Ä N
 ж H m ä 'Y ĩ J '
 S * ä H è 1. ј ǫ í 3
 1 6L К ó 11 ж 1 Ψ
 1 Ä = c
 H 1 C К
 H S ĩ
 12 ј Ğ ѡ TAP п
 'Y T ~ ĩ * ј
 TEGF 2 24 kD π J
 J I H^m ĩ Б^τ Ъ
 TEGF145 6T EGF21 6T EGF65 6T EGF2.6 6T EGF65

A ǫ
 1 ѡ ѡ . њ њ Ä J . Ψ Ъ
 ä Ъ 2.16 15 6 456 462.
 2 meta Ÿ J . Ψ Ъ Ъ 2.16 26
 23 5416 542..
 3 Ө ѡ . TEGF A њ њ Ä
 Ä J . Z Ъ 2.15 55 13 55 56.

~ . 7 1 ► Z^p

⊂ ũ B L ? R @ Ů B L 7 Ů G E P ? q α J

ψ f = 7 0 . / 02 0 . / 73 4 3 / 3 4 e

ψ / 3 2 1 3 4 R @ Ů B L 3 N A P 1 G E P 2 q G Q ? 三

“ 1 “ ψ ' O f R @ Ů B L G E P ? q α J

 ũ ä ε 2 0 , 65 # , 2 # ũ ä ε 7 6 , 65 # , R @ Ů B L ? 1 n

ψ ' O ε 0 / , 43 3 0 , 6 5 P ? q 1 n ψ ' O ε 3 6 , 46 6 . , 6 #

 1 n ψ ' O ε 5 . , 44 7 3 , 1 . 1 # n ψ ' O

ℋ P < ... 5 f T B D N A ψ ' O 66 . % e ε J 33 . 6 %

 ' O H 11 . 1 % ' Y τ P < ... 5 f T B D N A ' A I G R A s m

f T B D N A 1 I G R A s π ℋ α J “ ‘ 1 Å”

 ‘ w ' O ä ℋ α J f

 Å T B D N A Ů α J

?@QRP?AR M`hcartc Rm cvnjmpc rfc \_nnjga`gjrwm md R@UBL? _lb GEP?q rm rfc bq_elmqgq md
nsjkm_lpw rs`cpasjmqq gl rfc ucqrcpl Qqafs_l nj_rc_s, Kcrmbqn_rgc_lrq dpmk rfc nj_rc_s_pc_md rfc
ucqrcpl Qqafs_l dpmk ?npgp./6rm K_w 0./7 gl rfc 141 Fmqngr_j ucpc qcjcarcb glajsbgle /32 a_qcq md
rs`cpasjmqq \_lb134 a\_qcq md lml Urs`cpasjmqq, R@UBDØUNAP _lb GEP?q CJGQ? ucpc ncpdmpkcb
qgksjr_lcmsqjw, Rfc qclqrgtrw _lb qncagdgagrw md rfc rum kcrfmbq ucpc amkn_pcb _lb_l_jwxcbl`wQNNQ
pa rb m /32 /32cl

f q U ADPcNr s g l U ?

٢ 𐤔 𐤕

𐤕 KFB 𐤕 ATA𐤕 𐤕 TAN

𐤕 𐤕 A𐤕 f q U APN c r s g l U ? 𐤕 𐤕 A 𐤕 𐤕 𐤕

𐤕 0 . / 40 0 . / 71 𐤕 𐤕 KFB / . 𐤕

𐤕 𐤕 V ATA TAN 𐤕 𐤕 f q U APN c r s g l U ?

𐤕 𐤕 𐤕 PMA ; ? SA 𐤕 J ATA TA 𐤕 𐤕 ~ 𐤕 𐤕

𐤕 f q U APN c r s g l U ? 𐤕 𐤕 𐤕 TA 𐤕 𐤕 𐤕 / . 𐤕 KFB

𐤕 ATA 2 𐤕 23 , / 7 # ATA f q U APN 𐤕 ATA D c r s g l U ?

𐤕 ATA 𐤕 P<...5 1.4 𐤕 AACS 𐤕 𐤕 . | 21 𐤕 5.53 𐤕 32 𐤕 𐤕

𐤕 𐤕 TC 41 𐤕 39.42% 𐤕 TC hs CRP 𐤕 TC Fetuin A 𐤕 𐤕

𐤕 TC 𐤕 𐤕 P<...5 MHD hs CRP 𐤕 Fetuin A 𐤕 𐤕

CTC AUC 𐤕 𐤕 𐤕 .645 𐤕 .515 𐤕 .654 TC AUC 𐤕 𐤕 𐤕 .695 𐤕 .64. 𐤕 .951 hs CRP

𐤕 A CTCO 𐤕 AACS 𐤕 𐤕 𐤕 P<...5 Fetuin A 𐤕 J 𐤕 𐤕

P<...5 𐤕 MHD 𐤕 CTC TC 𐤕 𐤕 hs CRP 𐤕 Fetuin A 𐤕 𐤕 𐤕

𐤕 𐤕 𐤕 𐤕 CTC TC 𐤕 O 𐤕 𐤕 𐤕 𐤕 𐤕

𐤕 𐤕 𐤕 C𐤕 A

Pcj_rgmIqfgn `cruccl qcpsk fqIAPN _Ib DcrsGI ? jctcjq _Ib a_pbq_a t_jtc

a_jagdga_rgmI _Ib t_qasj_p a_jagdga_rgmI gI cjbcpiw n_rgcIrq ugrf fckmbg_jwqgq

XF?LE K_𐤕 XF?LE HgIefsg UCL Vg_mhsI

Bcn_prkcIr @cghgle Qfghgr_I Fmqngr_j A_ngr_j Kcbga_j Slgtcpqgrw@cghgle Afgl _ /...16

?@QRP?AR M`hcargtc Rm qrsbw rfc maasppclac md a_pbq_a t_jtc a_jagdga_rgmI ATA _Ib t_qasj_p
a_jagdga_rgmI TA gI cjbcpiw n_rgcIrq ugrf k_gIrcI_lac fckmbg_jwqgq KFB _Ib rm _I_jwxc rfc bg_elmqrga
t_jsc md qcpsk fwncpqclqgrtc AUpc_argtc nprmcgIqUAPN _Ib DcrsGI ? _Ib rfc amppcj_rgmI ugrf rfc bcepc md
a_jagdga_rgmI ,Kcrfmbq ? rmr_j md /.2 cjbcpiw n_rgcIrq ugrf KFB ufm ucpc rpc_rcb gI rfc fmqngr_j dpm k
Dc`ps_pw0./4 rm K_paf0./7 ucpc qcjcarb dmp apmqUqcargmI_j qrsbw , Rfc maasppclac md ATA _Ib TA ucpc
_qqcqqcb sqgle a_pbq_a amjnp Bmnnjcp sjrp_qmsIb _Ib _`bmkgl_j_jrcp_j VUpIbqrfc qctcpgrw u_q ct_js_rcb ,
Rfc qcpsk fqUAPN _Ib DcrsGI ? jctcjq md n_rgcIrq ucpc kc_qspdb rfc pcactcp mnep_rgle af_p_arcpqrga
asptc PMA u_q bp_uI _Ib rfc _pc_slbcp rfc asptc SA u_q a_jasj_rcb rm _I_jwxc rfc bg_elmqrga t_jsc
md rfc rum mI ATA _Ib TA , Rfc amppcj_rgmI `cruccl fqUAPN _Ib DcrsGI ? _Ib a_jagdga_rgmI bcepc md ATA
_Ib TA u_q qrsbgcb Pcqsirj ? kmle rfc /.2 cjbcpiw KFB n_rgcIrq 25 a_qc 23 , /7 # ucpc bg_elmqcb
ugrf ATA `w amjnp Bmnnjcp sjrp_qmsIb _Ib rfc qcpsk fqUAPN jctcjq md n_rgcIrq ugrf ATA u_q fgfcprf_l rf_r

𐤕 𐤕 5 / 6 2 0 0 3

𐤕 𐤕 𐤕 𐤕 𐤕 𐤕 𐤕 / . . . 16

𐤕 n 𐤕 C g k _v g 𐤕 /c2 3 5 0 > q g l _ , a l

P<...5 . The AACS score of 1.4 patients with MHD was . 21 points with an average of 5.53 ±1.32 points and there were 41 cases 39.42% with TC and the serum hs CRP level in patients with TC was higher than that in non TC patients while the serum Fetuin A level of TC patients was lower than that of non TC patients P<...5 . The AUC values of serum hs CRP Fetuin A and the combination of the two of elderly patients with MHD for CTC diagnosis were .645 .515 and .654 respectively and the AUC values for diagnosis of TC were .695 .64. and .951 respectively. Serum hs CRP level was significantly positively correlated with CTC severity and AACS score P<...5 and Fetuin A level was significantly negatively correlated with the two P<...5 . Conclusion Elderly patients with MHD often have CTC or TC. Among them hs CRP and Fetuin A may play an important role in the occurrence and progression of calcification and have good reference value for the diagnosis and severity assessment of CTC or TC.

KEY WORDS Hemodialysis Cardiac valve calcification Tascular calcification Hypersensitive C reactive protein Fetuin A

chronic renal failure CRF
4

U_{F H% U} T 3

	Н		Ė	τ	P<
	...5	2 ↓			

2.2 T2DM ٭ ٭ Ĩ Ė
w T2DM ٭ e ε
1 ٭ e ε 2 e ε 3 Θ
ε Ė ٭ ٭ UA ƒFINS ƒFCP Θ ε
٭ Ĥ Logistic ε Ũ ٭
UA ƒFINS ƒFCP T2DM ٭
٭ Ĩ Ė P<...5 3 ↓

$\bar{x} \pm s$ t Logistic
ε ε Ũ Person Ĥ Ũ
P<...5 τ ↓




2
2.1 2 UA ƒFINS ƒFCP
٭ UA ƒFINS ƒFCP

2.3 UA ƒFINS ƒFCP A ٭ Ĥ
Person Ĥ Ũ UA r=..365 ٭
FINS r=..426 ƒFCP r=..5.5 A ٭
٭ Ĥ P<...5 ٭ 1 ↓

5
6
5
4

		4		UA & FINS & FCP		A		b	
				$\bar{x} \pm s$					
		R_`jc 2		Amkn_pgsm l md scpsk S?		dgl s _lb DAN jc t cjs			
		ugrf kgapm t _sasj_p bgsc_scs		$\bar{x} \pm s$					
		q		n		UA		FINS mU/L	
		b		64		361.55 85..9		15.32 8.55	
		b		92		3....1 89.53		12..6 8.65	
		t e				6.559		9.529	
		P e				<...1		<...1	
						<...1		<...1	

2.5 UA & FINS & FCP A b Ā
 e t . N t 1 N t Person
 Ā Ů UA r=..353 & FINS r=..364 e
 FCP r=..464 A b v Ā P<...5
 2 j



IL 33/ST2 e PaCO₂ m
IL 33/ST2 e t
P<...5 j 2 j

2 3 $\bar{x} \pm s$
R_jc 0 Amkn_{pgsm}l md_{prcpj}j_jmmbe_sglbcxjc t cjs md
ss_{hcars}gl 1 epmsn $\bar{x} \pm s$

1	三	IL 33/ST2	e	$\bar{x} \pm s$			
R_`jc /	Amkn`pgsm  md GJQ11 - Q <del>R</del> p`rgms `cruccl rfc 0						
	epmsns md ss`hcars		$\bar{x} \pm s$				
Q	n	IL 33 pg/mL	ST2 pg/mL	IL 33/ST2 e			
COPD	9.	326.45	59.55	4.61	5.53	51.25	9.64
	1..	145.39	55.22	..94	5.11	154.65	21.66
t e		29.313	49.666			33.366	
P e							

		PaO ₂		PaCO ₂		PH	
ᐃ		mmHg		mmHg			
H GJ Q11 - Q _R e	45	45.35	55.2	62.34	5.22	5.1	5.23
GJ Q11 - Q _R e	45	53.21	55.66	54.21	5.9	5.26	5.21
	1..	99..2	5.51	39.55	54.12	5.39	5.9
F e		35.1		295.3		49.15	
P e		<...1		<...1		<...1	

2.2
IL 33/ST2 e H IL 33/ST2 e
PaO₂ PH H H PaCO₂ H
H IL 33/ST2 e PaO₂ PH

2.3
IL 33/ST2 e H IL 33/ST2 e
SOD CAT H H ROS
MDA H
t P<...5 j 3 j

		3	3			$\bar{x} \pm s$			
R _j c 1		Amkn _{pgsm} l	md rfc	jc t cjs	md mxgb _{rg} t c	srpcss gl	bga _{rmps} md	ss _{hcars} gl	1 epmsn $\bar{x} \pm s$
$\bar{\alpha}$		n	SOD	U/mL	CAT	mol/L	ROS	pg/mL	MDA nmol/mL
H	GJQ11 - Q _R e	45	132.65	516.31	5.26	5.62	41.25	55.4	5.66 5.51
	GJQ11 - Q _R e	45	216.46	542.2.	1..2.	5.51	3..16	55.49	3.59 5.53
		1..	452.19	559.34	22.56	54.3.	13.52	51.66	2.16 5.42
	F e		625.5		532.3		532.1		693.1
	P e		<...1		<...1		<...1		<...1

0 2 AMNB GJQ11 - Q_R e A
N_M NF A U
AMNB GJQ11 - Q_R e A
N_M NF V A A N_{AM}
V A A A Q QMB A?R
V A A PMQ KB? V A
t P<...5 j 4 j

4 COPD IL 33/ST2 e A e
A A

3
i
j A COPD H e H
A COPD
w ; PaCO₂ 6 5 j
COPD A y H
e o A y
A O E A 6 9 j
COPD H y y
w w "E e y /
y n y A A y
COPD w K 1. 11 j y
A "A " w w ; "H

Table 4 Correlation of IL 33 /ST2 ratio with blood gas index and degree of oxidative stress in patients with severe COPD

	PaO ₂	PaCO ₂	PH	SOD	CAT	ROS	MDA
IL 33/ST2 e	..554	..661	..523	..66.	..6.5	..564	..511
P e	...2	9	0	5	...12	...19	1

P<...5 .

Conclusion miR 26b 3p is highly expressed in gliomas which may target the regulation of TRA2B expression and inhibit the proliferation and metastasis of glioma cells. MiR 26b 3p plays an important physiological role in the development of gliomas.

KEY WORDS Glioma MiR 26b 3p TRA2B

α γ γ ~ O
κ λ | f 1 2 j ~ π ψ
"A π Ā 3 j
ϖ ζ ß 'Y 1 4 Ā ɔ
ǰ w ɔ щ m ɐ
í * 4 j Ğ
π 1 γ Ж ɔ
~ Ÿ j RNA miRNAs ε
2. | 22nt RNA miRNAs 'A mRNA
' ь mRNA 5 j miRNAs Ě ɐ
Θ ɔ A Ũ ɔ ɐ ψ ě H m
"Ω Ğ ψ Ě
τ 6 j miR 26b 3p ɔ i ψ

$\bar{x} \pm s$ n
 χ^2 $P < \dots 5$ ε τ $\downarrow$ $\tilde{U}$
 2
 2.1 'Y HE 'Y 1 'Y
 HE $\bar{n}$ 'O
 $\tilde{U}$
 $\Delta 1 \downarrow$

μ miR 26b 3p mimic miR26b 3p
 A

2.2 miR 26b 3p A TRA2B Ψ
 q PCR 1 'Y Ψ miR
 26b 3p $\bar{n}$ Ψ φ
 $\bar{H}$ τ $P < \dots 5$
 Ψ TRA2B
 μ $\bar{H}$ τ $P < \dots 5$
 2 $\downarrow$ m Ψ miR 26b 3p A TRA2B
 $\tilde{U}$ $\bar{n}$ miR 26b 3p A TRA2B
 $\bar{A}$ $r = -\dots 55$. $P < \dots 5$ $\Delta 2 \downarrow$
 2.3 $\sim$ SHG 44 Ψ miR 26b 3p A TRA2B

α q PCR $\sim$ miR 26b 3p
 miR 26b 3p inhibitor Ψ miR 26b 3p

Morganella morganii M. morganii


nii Morganella Π^m

Н ж 1 ε ж 1
γ φ^m Ů Н ψ 1
Ψ Θ j e ζ 1
K i e ħ H 1 ж "H a Ĩ
ё
Б 1 Ĩ 23 j Ä Q 2
UÄ jfdt4 u\

> 5124*8A8#006 1yM ITM %TF#\$pHC™1 @

mM 4 L 1. $\hat{A}$ Th . λ † =2/ †

HlyA 6
HlyB 6 HlyC 6 HlyD Ω Ω 1 PCR
 κ I 1. L ; 3.2 L ddH₂O 1 L ξ
DNA 3. ng/ L Θ ε .5 L dNTP 1.



Hly ε
HlyA HlyB HlyC HlyD ε
HlyB ε ε æ ε ↓ He η rA η D 'Y ž v γ p o 7 ˘ ñ

Ω /ρ Ö⁰ Δ⁰ ⚡ /

ث ه PL? j l a PL? I İ j

= J L1 6S6 5 KE Ē ã ũ ε LA ı h e ψ LA w l c e _ r g t c q g P L ?

ه w B G J A q g P L j ? ۆ ı ~ 2 6 f N A P G J H ? 0 Q R ? 1 R C J G Q ?

ə Ψ G J U U c q r c p l @ j m u H O ? - I H O ? I n U Q R L ? R Q R L ? R

j ~ 2 6 f R p _ l q u ç j j Ω ۆ Ω

Ÿ j ~ 2 6 f A J L1 6S6 5 K E L A e ه

T P<...5 j A LN362 dJ65MG NC e ه

IL 6 αJAK2 αSTAT 3 mRNA π ə Ψ IL 6 π p JAK2/JAK2 ı

p STAT 3/STAT 3 T π P<...5 j ه B /SO 2 p ı ` <

$0. / 6 \pm 1$ $\check{A} \check{\omega} \quad 0. / 6. 0. 031$
 $\Theta \quad \pi H / , \quad A \quad 1 \quad \pm \quad 23. . 30$
 $0 , \quad A \quad 1 \quad \pm \quad 23. . 30$
 $\rho \quad n \Theta \quad \Omega \quad C g k / g j 7 5 1 . 4 2 . > o o , a m k$



3 d`# d` 1 6 `!€ f•Ñ2 0 166Df3 0 #Dg3\$6X1€€\$Ñ2 0 6 p`Đf•Ñ20@R\$ X`D04D/G F1 %6B@Y0 11`61'6 D Đ`Q2Dc1X0'6#4YF

/p ЙΩ⁰ / /

٢
٧ 4 ٥ Ж í ' "E Ж "E ٥1 ٥ Ж í О Ж О 1 3 3
' ε j 1 ' ѡ ѡ Ÿ ~
п 1 y * Ÿ j Ж "E R Q F Ъ
Ж О R Q F Ω һ Ъ P<...5 j Ж "E FBG ٥ ~ 1 h 1hPBG ٥
2hPBG ѡ ٥ HbA1c ѡ Ъ P<...5 Ж О 1
~ ѡ τ P>...5 j TSH 'A FBG ٤hPBG ٤hPBG ѡ HbA1c V
Ä P<...5 j Ж "E 1 Ж О y ' п Ъ P<...5 Ж "E
y w ѡ y ٥H' O I y ٥ y п S Ъ P<...5 j
' A ѡ ٥ 'Y Ä ' Ж п 1 y * п
٥ ѡ Ж "E Ÿ ε O j
ѡ ѡ п

Cddcarq md qs`ajg lga\_j rfwpmgb bwqds largm l gl j\_rc npcel\_law ml ej samqc kcr\_`mĭ
jgq k _lb k_rcpl_j npmelmqgq gl npcel_lr umkcl
JS Afs lkcj° XF?M Wsle_Ÿe W?LE Vś D?L Afs lw_l
/ ,Bcn_prkclr md m`qrcrpgaq Og lfs\_leb\_m dgpqr fmqrgr\_jOg lfs\_leb\_m Fc`cg Afgl_ .44...
0 , Og lfs_leb_m f_ge_le fmqrgrOg lfs_leb_m Fc`cg Afgl_ .44...

?@QRP?AR M5vH5cr gllb j v ٥ T. н k_Ä ж ѡ T mkcl
F ` nq j f ~ x f ~ j_rd ~

Çwq Ä lg b.

0 . / 4/.40?
Θ π H / , ← m | y ← . 4 4 . . .
0 , ← | ← . 4 4 . . .
° n Θ C g k _g j a z 0 4 1 , a m k

2

2.1

Ж "Е TSH Hb
Ж O TSH Ω Hb P<
...5 3 FT3 FT4
τ P>...5 ↓ 1 ↓

Ж "Е 5.
Ж O 62
F e
P e

2.2

Ж "Е FBG 1 hPBG 2 hPBG
HbA1c Hb E τ
P<...5 Ж O 1 ↓ 2 ↓
τ P>...5 ↓ 2 ↓

2.3

TSH A μ A μ FBG 1hPBG 2
2hPBG ψ HbA1c A μ A μ FBG 1hPBG 2
FT3 FT4 A FBG 1hPBG 2hPBG ψ HbA1c
A " P>...5 ↓ 3 ↓
2.4 3 Y Hb Y
Ж "Е Y Hb τ P<...5 Ж
O Y Hb

3 TSH FT3 FT4 A μ A
Table 3 Correlation between serum TSH FT3 FT4 and
glucose metabolism

		1 h PBG		2 h PBG		HbA1c	
r	P	r	P	r	P	r	P
..463		..354		..444		..666	
...65	..35.	..155	...99	..152	..11.	...49	..6.5
...25	..555	..115	...99	...35	..511	...52	..566

Ж "Е HbA1c τ P<
...5 ↓ 4 ↓

2.5

Ж "Е v *
Ж "Е v Hb O I v ψ v
Hb P<...5 Ж O
1 v * Y
τ P>...5 ↓ 5 ↓

3

m I ū Hb
+ i *m 5 6 ↓ i
world health organisation WHO
a "Е Hb ε 1.6% |2.9%
O Hb ε ...2% |..5% 9 ↓

GEDUP

Ÿ a b /p K⁰ 0 Ÿ K¹

 Ÿ"Œ Ÿ Ğ ɔ l ŋ GEDUPAŸ"Œ ɳ ɳ
Ÿ ~ Ä j = ɣ ɣ Ÿ"Œ 5 ʒ ʁĖ Ÿ"Œ
Ÿ"Œ 6 ʒ @NF ʁ ɔ ɛ Ÿ GEDUP Ÿ Ÿ
Ÿ"Œ Ÿ GEDUP AŸ"Œ Ÿ ~ Ä w ŸŸ"Œ ~
 ĩ Ğ j Ÿ"Œ Ÿ GEDUP H@NF
τ P<...1 j " í Ÿ Ÿ Ÿ Ÿ"Œ Ÿ IGF IR
 τ P<...5 j IGF IR ~ ɔ ɳ H l
 H H τ P<...5 j IGF IR ʌ Ÿ"Œ
 ɔ ɳ Ÿ l ĩ τ P<...5 j COV ɛ Ÿ
 í Ÿ ʁw Ÿ ɔ ɳ ĩ Ğ P<...5 j IGF IR
' ʁ Ÿ"Œ ɳ Ÿ ɳ ʁ l ʁ ɣ ĩ ɯ m
Ÿ w IGF IR ɱ ▼ ' ▼ s ,

s

 ± ɮ Ä Ÿ 0 . / 6 . 4 1 6 7 /
Θ π H / ÷ ɮ ± ± 2 5 1 / 1 0
 0 , m ɮ ± 2 3 . . 3 0
 1 ÷ ɮ ĩ ± ± 2 5 1 / 1 0
° n Θ Ÿ a b C g k d g j j 1 0 1 4 1 , a m k

$\chi^2 = 1.0$
 $P = 0.55$
 $P < 0.05$
 $P < 0.05$

1.3

SPSS 21.0
 $\bar{x} \pm s$
 Mann-Whitney
 $P < 0.05$

2

2.1 IGF-IR
 66.92% 51/54
 36.25% 29/6
 $P < 0.05$




Figure 1 IGF-IR protein immunohistochemistry results

2.2 IGF-IR
 $P < 0.05$

2.3 IGF-IR
 $P < 0.05$
 $P < 0.001$

Table 1 Comparison of expression rates of IGF-IR protein in prostate cancer tissues with different characteristics

	n	n=51	n=23	P
T2	32	16 56.25	14 43.55	
T3	35	26 54.29	9 25.51	
T4	5	5 100.00	0 0.00	
Gleason				
>5	45	34 52.34	13 25.66	
≤5	25	15 62.96	10 35.14	

Table 2 Relationship between the expression of IGF-IR protein and the prognosis of prostate cancer patients

	n	I	H	P
IGF-IR				
+	51	43 64.31	6 15.69	
-	23	14 43.46	9 56.52	
		13 55.5	4 22.5	
		<0.05	0.04	




Figure 2 Relationship between IGF-IR protein expression and biochemical recurrence survival rate in prostate cancer patients

2.4 IGF-IR
 $P < 0.05$




Table 3 COV regression analysis of influencing factors of survival time after prostate cancer surgery

	SE ^e	Walds ^e	P ^e	OR ^e	95%CI	
	.543	11.611	...1	...56	...16	..334
	.5.5	4.465	...34	2.925	1..63	5.696
	.663	1.266	..26.	..359	...5.	2..54
	.662	3.322	...66	4.614	..666	26..94

'Y Ā⁵⁶ ↓ IGF IR A IGF I ' ~ A
 ≡ m ~ m m ~
 PI3K/AKT IGF IR A I ' ~ ɔ
 ψ c
 B ɔ m Ē ~ 8
 ũ w ψ Ā Ē H⁹ ↓ J m ~ ε
 MAPK/ERK IGF IR ɔ ~ '
 m ~ ψ ɔ Ē 3 ɔ Ras 8
 Rad ~ Ĩ ' ɥ Ĩ m ~
 x MAPK/ERK
 8 ũ ɔ^{1.11} ↓ ǿ"Ω A IGF IR
 m ~ 8 'Ω II 'Ω 'Y
 Ā¹² ↓ IGF IR ' Ĩ Ē
 ψ 'Ω¹³ ↓
 n¹⁴ ɥ 6 ' ɔ IGF IR ψ
 m ~ ψ ɔ Ē 3 Ĩ ǿ"Ω n
 ψ ~ IGF IR ψ m ~ ψ
 ɔ Ē 3 ' H ɥ
 6 m ~ ↓ ǿ"Ω
 Ĵ O ~ †
 ↓ ε ~ †
 ε ~ ǿ"Ω IGF IR

U3Cn9BmDcUpEATW, 6-j} 6iQ, %7DdDQ+&2Aŋx ō vCE! 5 @

UÀ(UN5DfUUBJDCA2TtEE 4 u 4 EŽ 6EU Ž ÓÒ s0Đ 0`U• 4 UÈ 4•UỠ UÂ

kgPQ / NBAB

BS/ 23

Θ ε

Z Ъ

ρ

ك g a p m P Q R U Z Q / ۆ"Ω BS/ 23 Θ ψ ũ
"A ј Ё ۆ"Ω BS/ 23 ũ ε ek g P U LA ek g Z Q / ek g Z Q)/
n a B L k g Z Q)/n a B L ? U H غ 2 NBAB k g P U L A k g P U k g Z Q /
k g Z Q k g Z Q)/n a B L ? k g Z Q n a B L ? ek g Z Q)/n a B L ? U NBAB k g Z Q
n a B L ? U NBAB K R Q Ω w N A P NBAB k P L ?
u c q r c p l N B A B X w 1 غ k g Z Q / NBAB ~
' ј 'A ψ k g P U L A k g Z Q / Ω NBAB ψ
NBAB X w 1 غ w Ω H P <...5 A miR 421) pcDNA miR 421) pcDNA
PDCD4 Ω H PDCD4 P <...5 ј miR 421 ۆ"Ω DU145
Ё . Θ ~ "A PDCD4 miR 421 n m Θ ũ "A ј
Ä ۆ"Ω miR 421 PDCD4 غ

Cvncpgkclr_j qrsbw md kgPÎ20/ npmkmrcq rfc npmjgdcprgmI md npmqr_rc a_lacp
acjj jglc BS/23 `w r_pecrgle NBAB2

JG Xsmucg ESM F_le BCLE Af_m W?L Bmlejg_le RG?L @glog_le

Bcnprkclr md Spmjew Qf_lef_g Slgtcpqgrw md Kcbgaglc \$ Fc_jrf Qagclacq _ddjg_rcb Qgvrf Ncmjg
Fmqngr_jc_qr Qf_lef_g Afgl_ 0./1.4

?@QRP?AR M`hcartc Rm gltcqrge_rc rfc cddcar md kgapmPL?20/ kgPQ20/ ml rfc npmjgdcprgmI
md npmqr_rc a_lacp acjj jglc BS23 _lb grq nmrcrlrg_j kmjcasj_p kcaf_lgqkKcrfmbq Npmqr_rc a_lacp BS23
acjjj ucpc asjrscpb _lb bgtgcbcb glrm amlrpmj epmsrkPQlce_rgtc amlrpmjLA epmsn kgPQ20/ epmsn kgPQ
20/) naBL? epmsn kgPQ20/) naBL? U npmep_k kcb acjj bc_rf ecB NBAB2 epmsn , KgPQLA epmsn u_q
rp_lqdcarcb ugrf kgPQLA kgPQ20/ epmsn u_q rp_lqdcarcb ugrf kgPQ20/ kgPQ20/) naBL? epmsn u_q
rp_lqdcarcb ugrf kgPQ20/ _lb naBL? nj_qkqb kgPQ20/) naBL? UNBAB epmsn u_q rp_lqdcarcb ugrf kgPQ20/
_lb naBL? UNBAB nj_qkqb Acjj npmjgdcprgmI _argtgrw u_q kc_qspcb `w KRQNBAB2 kPL? cvnpcqggml
u_q kc_qspcb `w DOUNAPNBAB2 npmrcgl cvnpcqggml u\_q bcrcarcb `w Ucqrcl `jmr\_lb rfc r\_pecr `glbgle md
kgPQ20/ _lb NBAB2 u_q tcpgdqcb `w bms`jc jsagdcprqc pcnmprec ecle cvnpgkclrcqsjrj Amkn_pcb ugrf rfc
amlrpmj epmsn _lb kgPQLA epmsnfc npmjgdcprgmI _argtgrw md rfc kgPQ20/ epmsn glapc_qcb , Rfc cvnpcqggml
jctcj md NBAB2 _lb rfc djsmpcqaclac _argtgrw md ugjbUrnw NBAB2 bms`jc jsagdcprqc pcnmprec ecle bcapc_qcb
P<...5 . Compared with miR 421) pcDNA group the proliferation activity of miR 421) pcDNA PDCD4

э ґ ҃ FKQDQD / 4э ґ ҃ ж ж 1э Z
J n N I H . / 2 5 W
Θ π H э ґ Ä ж ҃ Z 0 . / 1 . 4
ρ n Θ C g k x 2 7 2 5 7 4 5 1 3 2 n k

$P < 0.05$. Conclusion miR-421 can promote the proliferation of prostate cancer cell line DU145 by targeting the inhibition of PDCD

P<...5 'A miR 421) pcD
 NA miR 421) pcDNA PDCD4 DU145
 Ψ PDCD4 24 46 62 h
 Ω Η P<...5 ↓ 4 ↓

3

miR 'A η η Ḃ ɔ Ḃ
 Ḃ miR ~
 Ğ Q Ğ η . Θ ↓
 miR 421 m Ė . Θ miR ǫ"Ω
 ʁ ʁ ʁ Ψ √
 † 4 6 1. 5
 miR 421 † ʁ ʁ
 Ė . Θ ^{11 13} w ɔ miR 421
 η η . Θ ↓
 Ů ɓ miR 421 ǫ"Ω
 Ψ Θ ʁ "A ↓ I Ė ǫ"Ω
 DU145 Ψ miR 421
 miR 421 ~ DU145 Ω
 miR 421 ǫ"Ω DU1415
 Ė . Θ 'A ǫ"Ω Ψ miR 421
 † √' ʁ 'A ɐ ɤ miR 421
 . Θ m ↓
 miR * ɐ Θ
 Ğ miR 'A Ğ mRNA

3

G J/ψ G J/ψ G D U U

6<...5

/ Op /

٢ ٤ ٤ ٧ G D U U †
Ψ θ e ψ A ~ Ā j = γ 0 . / 47 0 . / 6/ / 7 Q †
ε † ' 'Y 7 Q † † ε j 0 A ^ I θ
í † G J/ψ G J/ψ G D U U "A ɔ Θ PMA ũ ~ π
m 'A ' † θ e " ~ / n θ n † ~
Q n c _ p k _ l ũ ~ A † ~ n Ā j †
G J/ψ G J/ψ G D U U H P<...5 IL 1 u d L 1. dFN Ů † É |
AUC 3 ' † ε 55.15% θ ε 64.56% í ũ ε θ |æ
θ ũ ɔ ε ψ H ũ ɔ θ † IL 1 u d L 1. dFN Ů † ε ũ

ψ † ж É i 0 . / 6 w p a
θ π H / , ± ψ † ± ψ † j † ± 2 3
0 ± w ψ † † ± w 0 / . . 0 7
° n θ Cg k _ w g _ j m a 1 f 1 _ / l 6 7 4 1 , a m k

	95%CI	P e	e	e	%	e	%
	..544 ..662	<... .1	>5.23 pg/mL	56.52		95.65	
	..635 ..551	<... .1	>29.44 pg/mL	5..65		63..4	
	..655 ..6.5	<... .1	>..29 pg/mL	64.13		61.52	

4 " i t											
R_jc 2 Amkn_pgsml md scpsk glbcxcs md pc_sr a_lacp n_rgc lrs ugrf bgddcpc l r ajglga_j af_p_arcpgsrgas										X±s	
	n	IL 1u pg/mL	t e	P e	IL 1.	t e	P e	IFN U pg/mL	t e	P e	
	52	11.2 \$5.19	1.511	..134	43.42 \$16.23	1.456	..144	..34 \$..21	1.252	..214	
	4.	9.46 \$4.36			36.52 \$15.19			..29 \$..16			
	61	13.54 \$5.65	6.546	<....1	46..3 \$16..5	4.111	<....1	..41 \$..23	6.352	<....1	
	31	4..5 \$2.69			31.96 \$14.35			..14 \$..5			
	63	13.26 \$6..2	5.699	<....1	46.92 \$16..6	5.164	<....1	..36 \$..2.	4.564	<....1	
	29	3.96 \$2.65			29..6 \$13.62			..19 \$..11			
	59	13.52 \$5.26	9.52.	<....1	46.66 \$15.24	6....	<....1	..42 \$..23	6.699	<....1	
	33	4.32 \$2.35			25.56 \$14..5			..14 \$..9			

5 " ~ t										X±s ne - kJ	
R_jc 3 Amkn_pgsml md scpsk glbcxcs gl pc_sr a_lacp n_rgc lrs ugrf bgddcpc l r npmelmsgs										X±s ne - kJ	
	n	IL 1u	IL 1.	IFN U							
/	n	13	14.62 \$5.53	59.12 \$16..3	..51 \$..25						
/	n	59	9.61 \$2.94	36.36 \$13.56	..29 \$..14						
t e			5..53	4.616	4.619						
P e			<....1	<....1	<....1						

0 4 ~ A t ~ n Ā
Qnc_pk_l Ā Ũ GJ U ur r=
..425 dP<....1 dL 1. r=..4.6 dP<....1 dFN U
r=..392 dP<....1 A t ~ n V
Ā j

3

t ε n ā
23% H~ H 'Y
J H • 9 11 j
í 'O n ' 1 Ē
Ē 'Y Ā I ɔ K~ x Ж
Ē ɔ ɔ Ē
y ɔ ɔ
ψ 12 13 j IL 1u ε 4 ψ
1 ζ ɔ π Ũ
ζ ' 2 Ĩ u A Ĩ
IL 1u ɔ I ' ~ ' K ɔ I m ~ H
ψ 14 j 15
t IL 1u H t
ψ f I 'Y A t
'Y Ā IL 1u ' ɔ A t n
ɔ j W 16 n ɔ

P<...5 . The AMH AFC and endometrial thickness of the observation group were lower than those of the control group P<...5 . CD3⁺ HLA DR cells in peripheral blood were negatively correlated with serum AMH AFC and endometrial thickness P<...5 . Conclusion Peripheral blood CD3⁺HLA DR cells are abnormally elevated expression in patients with POI and have a certain correlation with immune disorders and ovarian function in patients with POI. It is expected to become an important T cell subset that regulates the immune response of POI patients and improves ovarian reserve function.

KEY WORDS CD3⁺ HLA DR cells Early onset ovarian insufficiency Humoral immunity Cellular immunity Ovarian function Endometrial thickness

premature ovarian insufficiency POI 4. 卵泡刺激素 FSH 雌二醇 E2 促黄体生成素 LH 孕酮 P 睾酮 T 泌乳素 PRL 生长激素 GH 甲状腺激素 TH 皮质醇 CORT 肾上腺素 AD 去甲肾上腺素 NE 多巴胺 DA 5-羟色胺 5-HT 谷氨酸 GABA 乙酰胆碱 ACh 多巴胺 DA 5-羟色胺 5-HT 谷氨酸 GABA 乙酰胆碱 ACh 多巴胺 DA 5-羟色胺 5-HT 谷氨酸 GABA 乙酰胆碱 ACh



A w q F a w K N T L R U n p m @ L R N C K G

0 . / 7 ± ► ¢ ıЖ ѿ 0 . / 7 đ 0 đ 4 5
Θ π Η / , Z ᵐ ı ı İ Z ± 0 5 / / 0 4
0 , Z ᵐ ı ı Z ± 0 5 / / 0 4
º ƙ Θ Cđ k _jggj ı đ 6 đ 1 4 1 ¢ , a m k

	n=34	ISR	n=1.3	P e
	6 15.6	16 15.6		..254
	5 14.5	12 11.6		..126
	4 111.6	6 5.6		...63

2.5 ISR Ğ Logistic ¢ Ů
π Ğ Ů ĩ ISR Ğ 6
f † 'O Ń Logistic ¢ Ů †
♥ 64 ' 6 64 ' Ğ Ą
'A ISR n \ Ą P<
...5 † MPT CysC Hcy NLR NT
proBNP LDL C ApoB Ą CysC
MP T NT proBNP NLR Hcy

nqWL..

Table 10. Results of the model fit for the 1986-1987 season.

	Model	AIC	BIC	LRT	P-value	R-squared	Adjusted R-squared	F-statistic	p-value	Odds Ratio	CI
Overall	Model 1	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 2	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 3	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 4	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 5	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 6	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 7	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 8	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 9	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 10	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 11	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 12	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 13	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 14	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 15	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 16	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 17	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 18	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 19	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 20	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 21	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 22	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 23	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 24	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 25	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 26	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 27	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 28	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 29	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 30	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 31	100.0	100.0	100.0	0.000	0.000	-0.000	0.000	0.000	1.000	(0.000, 0.000)
Overall	Model 32	100.0	100.0	100.0	0.000	0.000	-0.000	0			

Θ π H $/, \perp$ $\vee$ $\vdash$ Ψ $\perp$ i $35.0.4$
 $0, \perp$ $\vee$ $\vdash$ Ψ $\perp$ i $35.0.4$
 ρ $m\Theta$ $Cgkxgllejghlqagmkm>$

P	Θ	↳	Ä	Logistic	ε	Ů	È
	PI	RI	ε	ur HCG	ϑ	A	
		Ä		P<...5	↓	2 ↓	

↳
NG
PG
ur FAE
P

2.3 ↳ Ψ

ROC Ů
; Area under the curve
AUC ε ..693 PI>..59 RI>..46 ε ur HCG =
69.65 mIU/mL ε P =25.41 ng/mL 3
' ŷ 1 ↓

X±s ϑ RI ϑPI Ψ ur hCG ϑ A
Ä Ä Logistic ε Ů
Ů ϑ Θ Receiver operating charac
teristic ROC Ů Ψ ϑ e P<...5 ε
τ ↓


2

2.1 ≡ ↳ Ψ

		PI	RI	ur HCG	ϑ
		H	P<...5 ↓	1 ↓	
2	≡	↳	Ψ	n	$\bar{x} \pm s$
R_`jc 0	Amkn_pgsmI	md	sjrp_smsIb	n_p_krcrps_l	b scpsk
gIbga_rmps	`crucci	r	fc	rum	epmsns
				n	$\bar{x} \pm s$
Ǻ	n	PI	RI	ur HCG mIU/mL	P ng/mL
	62	..66 §..33	..52 §..14	5..61 §5.15	15.65 §3.19
	62	..69 §..25	..4. §...9	9..22 §21.39	26.69 §6.35
t e		3.5.9	5.655	11.699	12.2.2
P e		<....1	<....1	<....1	<....1

2.2 ↳ Ψ A Ä
w Θ ξ ↳ PI RI ur HCG ε

2.4 " ↳ Ψ
PI RI H
ur HCG ϑ P<...5 ↓ 3 ↓



K K N G D HMGB1 TLR4 mRNA

ý / ÷ Z 7 / 0

ج J L ٧ ٲ 7 K K N ٭ ٲ G D ٲ ٲ

@ / F K E @ ٭ R m j ٲ I 2 R J ٲ ٲ ٲ A ٲ ٲ = ٲ 0 . / 5

6 0 . / 75 4 ٲ J L J L ٲ 1 ٲ J L ٲ

ٲ ٲ 0 . . 1 ٲ ٲ ٲ G Q L - ٲ N Q 1 L ٲ ٲ ٲ

K K N G D ٲ HMGB1 mRNA ٲ TLR4 mRNA Logistic ٲ ٲ ٲ ٲ

Pearson ٲ ٲ ٲ ROC ٲ ROC ; AUC ٲ ٲ LN ٲ

ٲ ٲ ٲ MMP9 ٲ FN ٲ HMGB1 mRNA ٲ TLR4 mRNA LN

P<...5

0 . / 6 ٲ ٲ ٲ / 6 0 1 . . 2 / . 0 7 4


ٲ ٲ ٲ / , ٲ ٲ ٲ ٲ ٲ ٲ ٲ ٲ ٲ 2 5 1 . . .

0 ٲ P ٲ ٲ ٲ ٲ ٲ ٲ 0 . . . 7 0

ٲ ٲ ٲ ÷ Z 7 C g k ٲ ٲ j ٲ ٲ ٲ > q g I _ , a m k , a I

	n	/	LN	ISN/RPS.2..3	Ů
LN	63	25/36	34.69 §12.35	16..6 §4.46	5.21 §1..6
t e	34	12/22	35..5 §13.95	15.91 §6.41	5.33 §1.14
P e		.525	...56	..135	..512
		.469	..954	..693	..61.

Activity P.Y. “Free Yò” ò T_MY_NW_{GB}•) @DUP



5 ROC ũ

Table 5 ROC analysis results

	95%CI	Z e	P e	e	e	%	e	%
.535 .555	2.569	...1.	>466.5	55.66			55.56	
.636 .643	4.523	1	>241.92	65.65			51.43	
.663 .659	5.626	1	>3.35	59.41			66.65	
.651 .655	5.256	1	>1.96	5....			93.65	

LN	ψ LN'	Ψ	J Tra	π	IFN γ	LN'	θ)α
H ⁹	Ä T̄ 15.	ζ SLE	π MMP9'	Ψ	ν	A LN π	dLN
SLE	A SLE			ũ	Ä J	¹⁶	O IFN γ
Ä J Ugarte Berxal E ^{1.}	'O MMP9'						Ψ ν
x'	Ψ C1	K J Mao WM ¹¹			φ φ	γ H IFN γ	~ w
m meta ũ	π SLE	ν		; '		ǻ	ν' IFN γA
MMP9 H SLE ж J MMP9					K Ä	J IFN γ	LN
A SLE Ä'	A LN T Ä J	π				' ε í	LN'
MMP9 LN'	θ)α	Ψ		w λ J			
ν A LN π dLN ũ				TLR4 ζ	H π	δ	' u
Ä J ~ ¹²	MMP9 siRNA			Cl ũ	ψ İ	H	ǻ
O	π	~		x A x ж I x	Ψ	ǻ	
I e	"E			Θ J π	HMGB1 θTLR4	LN'	
MMP 9'	"E O K l				θ)α	Ψ ν	A LN π
ν' b'	T̄ J LN				dLN ũ	Ä J Song E ¹⁵	
m x ğ Bx λ A				TLR4'	HMGB1		
T̄ π J IFN γ e Ψ ζ ğ φ				Ψ I			
m ¹³	SLE				J'	LN'	
π A	Ψ			AUC HMGB1 mRNA >TLR4 mRNA	' ε í		
IFN γ	π			LN'	w λ J e		
¹⁴	Ψ ж λ Rg1 "Ä IFN γ y			H	ζ	' m	
π Th1/Th2 ψ ǻ ν J				J			
' IFN γ' K J				ν LN	ν Ψ MMP9 θFN γθ		
Wen S ¹⁵	IFN γ LN ν e			HMGB1 θTLR4	A ũ Ä'	Θ	
Ψ ν A Y Ä J				ε λ J			

? I e 2 A R J 2 U B

đ º

٧ KL 2 ? I e 2 B j R
Q 2 A R J 2 U 0 0 B1 0 0 M F B1 A " H ' Ä j = 7 0 . / 5 /
0 . / 7 6 K L / 0 3 e P * è S ? K L 2 3 n
G K L 2 3 n Q K L 2 3 5 7 ' 4 I 8 1 2 3 0 e
~ 6 " H 9 8 R C E " H ' ? I e 2 A R J 2 U
0 0 M F B1 3 e Ä j 1 6 0 2 f 6 R E 6 R A 6 A P C 6
@ S L 7 P > ... 5 P L A È 7 P < ... 5
~ A È 7 P < ... 5 j 3 P T 6 T 6 A P T T 7
F I B 7 D D È 7 P < ... 5 A
" H 8 È 7 P < ... 5 j 4 K e 6 R e 6 U 6 M A
È 7 P < ... 5 j 4 A n g p t l 4 6 C T L A 4 7 2 5 O H D 3 È
7 P < ... 5 j Ä 3 A n g p t l 4 6 C T L A 4 7 2 5 O H D 3 3 6 A T E G ~ È
Ä j A n g p t l 4 6 C T L A 4 7 D H 6 7 7 5 " H ' 7
7 È í 7 j
7 4 T Q 4 2 5
D 3 " H ' 7

Ampccj_rgmI `cruccI bccargmI md ?Ienrj2 ARJ? Î 2 _Ib tgr_kgl B _Ib
am_esj_rgmI dslargmI gl n_rgcIrg ugrf kck`p_lmsq lcnfpmn_rfw
HG? JgkgIº XF?M Asg UCG Bg D?LE Vg_md_Ie
Bcn_prkclr md Lcnfpmjmew NcmnjcBq Fmqnqr_j gl A_lexfms AgnA_lexfms Fc`cg AfgI_ .4/...

?@QRP?AR M`hcartc Rm gltcgrge_rc rfc jctcjq md _legmnmgrgl Ujgic nprc2I ?Ienrj2 qcpsk
awrmrmvga RjgkfnQIS P 6 M P 0 P ?leo Î

ñ 3 / 5 0 1 . 0 / 0 0
0 7 H 8 7 I 4 / . . .
º n 0 6 C g k j g 6 f . 6 / 5 d 4 7 , a m k

$P > .05$ and the differences in PLA levels were statistically significant $P < .05$. There was a statistically significant difference between the laboratory indexes of patients with membranous nephropathy and the control group $P < .05$. There was no significant difference in the levels of PT TT APTT and FIB in the three groups of patients with MN. The difference in D-D levels was statistically significant $P < .05$. MN patients had a statistically significant difference in coagulation factor indicators compared with the control group $P < .05$. The K value R value U' angle and MA were significantly different between the 4 groups $P < .05$. The differences in Angptl4 CTLA-4 and 25-OH-D3 levels were statistically significant in the four groups $P < .05$. Correlation analysis showed that Angptl4 CTLA-4 and 25-OH-D3 had significant correlations with TEG indicators respectively. Conclusion The determination of Angptl4 CTLA-4 and vitamin D has important clinical significance for the diagnosis treatment and monitoring of changes in coagulation function in patients with membranous nephropathy.

KEY WORDS Atypical peritoneal nephropathy Angiopoietin like protein 4 Serum cytotoxic T lymphocyte antigen 4 25 hydroxyvitamin D3 Coagulation function

í ñ Ç Ğ İ ' Ũ ε * ě
Undetermined atypical membranous ne
phropathy UAMN ³ ñ Idiopathic
membranous nephropathy IMN 1 ñ
Secondary membranous nephropathy SMN 1 2 ↓
ę Ψ UAMN ñ IMN 1 SMN ñ
‘Υ “ † ↓ MN
H 1 D J I D dimer D D
“” “H ñ
3 ↓ Ğ H MN
³ 1 || Ũ ↓
4 Angiopoietin like protein 4 Angptl4 ε
É γ ę A
Υ ‘Υ Ă 4 ↓ 5 IMN
Ψ T Ç 4 Cyto
toxic T lymphocyte associated antigen 4 CTLA 4
H Ÿ ↓ 25 D3 25 OH
D3 D I Ĩ ζ ę H
³ μ ψ I x κ Y
5

P<

...5 ↓ 2 ↓

2.3 ~ TEG "H ' A IMN SMN UAMN K e R e H U' dMA e T P<...5 ↓ A IMN SMN UAMN K e R e H U' dMA e T P<...5 3 ↓

2.4 ~ Angptl4 CTLA 4 U 25 OH D3 UAMN lIMN lSMN Angptl4 e 25 OH D3 H CTLA 4 H H E O

	n	Angptl4
	4.	5.6 §1.3
	4.	4.5 §.9 ^a
	4.	
	4.	
F ^e		
P ^e		

@SLBUBJ_aAFC

ر
پ
ؤ
ت
@SLBUBJ_aAFC
ي
ه ه ج
٧ ٠ . / ٢٢ ٠ . / ٧٤ ٠ ٠ ٢
آ ~ ١ ب ي ي ه / ٣ ٢ ه ٥ ٥ ج ٠ آ @Sb
BUBJ_aAFC ه A ر ?N?AFC ي ه ' ' KMBQ ي ي ~
A ?N?AFC KMBQ ي آ ه ي ه ه BUBJ_ga
@SLA ?N?AFC KMBQ ي ي آ qAFC?N?AFC KMBQ ي ي آ P<...5 آ 5d
BUNAUC ه ..61. >sCHE ..6.6 >D D ..56. >Lac ..555 3. d~ w ROC ي ه ي ه •
ه • BUN dD Lac CHE • ه • P<...5 ج
BUN dD Lac CHE ي ي ' ه ي ي
آ D J I ت

Rfc npcbgargtc t_jsc md qcpsk @SL BÎB J_a qAFC jctcjq gl rfc qsptgt_j md
qctcpc nlcskmlg_

X F?LE Hg_laf_leJ?G W_l`m JG N_lqfg R?L @glehsl

Bcnprkclr md apgrga_j_a_pcbmlees_l ncmnjBq fmqngr_jBmlees_l E_lebmle Afgl_ 301...

?@QRP?AR M`hargtc Rm gltcqrge_rc rfc npcbgargtc t_jsc md qcpsk spc_ lgrpmec@SL BUBJ
bgkcp BUBJ `jmb j_ar J_a _lb afmjglcqrq_qc qAFC jctcjq gl rfc qsptgt_j qr_rs md n_rgclrq ugrf
qctcpc nlcskmlg_ ,Kcrfmbq ? rmr_j md 002 n_rgclrq ugrf qctcpc nlcskmlg_ _bkgrcb rm msp fmqngr_j dpm k
?npj0./2 rm Hslc0./7 ucpc qcjcarb_q rfc pcqc_paf m`hcarq?aampbgle rm rfc qsptgt_j qr_rs _lr. b_wq_drcp
_bkqqgm l rfcw ucpc bgtgcb g lrm qsptgt_j epmsn/30 a_qc _lb bc_rf epmsn 50 a_qc , Rfc qcpsk @SL
BB J_a qAFC jctcjq _asrc nfwqgmjmw _lb afpmlga fc_jrf ?N?AFC n qampcq _lb ksrgnnc mpe_l
bwqslargml qwlbpmkc KMBQ qampcq_r bgddcpclr _bkqqgm l rgkq ucpc amkn_pcb `cruccl rfc rum epmsnq
Rfc amppcj_rgm l md qcpsk glbcvcq ugrf ?N?AFC _lb KMBQ qampcq _lb rfcgp npcbgargtc t_jsc dmp rfc
qsptgt_j qr_rs md qctcpc nlcskmlg_ ucpc _l_jwclp_cqsjr Qcpsk BUBJ_a @SL ucpc nmqgrtcjw
amppcj_rcb ugrf ?N?AFC KMBQ qampcq _lb qAFC u_q lce_rgtc jw amppcj_rcb ugrf ?N?AFC KMBQ
qampcq P<...5 . On the seventh day od admission AUC od BUN ..61. > sCHE ..6.6 > D D ..56. >
Lac ..555 . After 3. days od dollou up the best cut odd value od the ROC curve uas divided into low risk
group and high risk group and the survival curves od serum BUN D D Lac sCHE high risk group and low
risk group uere signidicantly didderent P<...5 . Conclusio n Serum BUN D D Lac and sCHE levels are
abnormally expressed in patients uith severe pneumonia which can provide some data support dor clinical

Z Ж n 0 . / 7 3 . 5 / 3 . . / 1 4 6
Θ π Η Ζ ж т т Z Z 3 0 1 . . .
ρ nΘ C g k 5 ٢ j. 0 6 / 0 3 5 > o o , a m k

	n	BUN
	152	
	52	
t ^e		
P ^e		
	152	
H	52	
t ^e		
P ^e		
	152	
H	52	
t ^e		
P ^e		
	152	
H	52	
t ^e		
P ^e		

Table 5 Factors influencing the survival of severe pneumonia

	S.E ^e	Wald/	P ^e	OR ^e	95%CI
	.416		<...1	.361	.261 .496
	.3.2		<...1	.525	.342 .6.5
	.355		<...1	2.464	1.54. 4...5
	.391		<...1	2.2.6	1.256 3.613
	.455		<...1	3.396	2..24 5.5.6
	.249		<...1	.595	.369 .911
	.514		<...1	3.951	2.351 6.5.6
	.519		<...1	5.136	3..13 6.555




Figure 1 ROC curve

2.5 $\tilde{u}$ Lac sCHE $\bullet$ Θ_H $\bullet$
 $\bar{y}$ e $\tilde{u}$ ε H τ $P<...1$ $\downarrow$ Δ 2 $\downarrow$
 $\bullet$ Θ $\bullet$ KM $\tilde{u}$ BUN dD D Θ




Figure 2 Survival curve

3 $\mathcal{K}$ η τ $\mathcal{O}$ Ψ γ $\tilde{A}$ $\downarrow$
 H η $\tilde{\Omega}$ η $\tilde{\chi}$ η I A Θ γ $\downarrow$ Θ
 η $\tilde{\chi}$ η I A Θ γ $\downarrow$ Θ

expression of HSPA2 and IGFBP 2 proteins in pancreatic cancer tissues is positively correlated with TNM stage and lymph node metastasis and negatively correlated with the degree of differentiation. Monitoring the protein expression levels can provide a diagnostic basis for clinical judgment of disease development.

KEY WORDS Heat shock protein A2 Insulin like growth factor binding protein Pancreatic cancer
TNM staging Degree of differentiation Tumor

1.2 1.3 1.4 1.5 1.6

4. g/L ;

5 min

HSPA2 dIGFBP 2

35

phos

PBS

3

3. min

1.3

1.4

1.5

1.6

SPSS 22..

<...5

τ

2.3 HSPA2 dGFBP 2

2.2 HSPA2 dGFBP 2

ROC AUC 0.669 0.54

93.55% 66.3.%

Table 1 Expression of HspA 2 and IGFBP 2 in three groups

	n	%
HSPA2	66	65.35
IGFBP 2	56	59.59
HSPA2	35	39.55
IGFBP 2	39	44.32
HSPA2	16	16.55
IGFBP 2	22	22.92
P	49.496	66.592
P	<0.001	<0.001




Figure 1 pathology of pancreatic cancer normal pancreatic tissue beside pancreatic cancer and benign pancreatic tumor

2 HSPA2 dGFBP 2

Table 2 diagnostic value of HspA 2 and IGFBP 2 protein in pancreatic cancer


	n	%
HSPA2	195	51.36
IGFBP 2	212	55.51
P	2.165	19.692
P	0.336	0.544

2.4 HSPA2 dGFBP 2

Pearson A

TNM

P<0.05



3

HSPA2

IGFBP 2

P

45% 16.6%

Sciegliniska D

HSPA2

IGFBP 2

n=66

31

‡

NM

Q.

P ð à

n=66

i P ð à•

L Â ó 3 Ñ•5 à
O •

WÂ 36 C3 Ç Ñ•5 Â
O •

L Â 6 Ž Ô@5 / .

ρ

٢

٣ II

R 1 ?

/ 4 1 2 0 . . / 3

2 3

ρ

C g k _ / 0 3 0 6 . 7 3 0 0 > o o , a m k

P<...5 . The estrogen and progesterone levels in high dose group were 42.39 ~~54.31~~ pg/mL and .65 ~~5.4~~ ng/mL respectively which were significantly lower than those in other groups P<...5 . HE staining showed that after high dose Ox HDL was given to PCOS rats the cyst follicles further increased the arrangement of granulosa cells was looser and the pathological symptoms of ovaries in rats were aggravated. Hoechst33256 staining showed that the apoptotic level in high dose group was significantly higher than that in other groups P<...5 . RT-PCR showed that Ox HDL could inhibit the expression of Bcl-2 FSHR and StAR genes in granulosa cells P<...5 and Ox HDL could promote the expression of Bax genes in granulosa cells P<...5 . Western blot showed that Ox HDL could inhibit the expression of Bcl-2 FSHR StAR protein in granulosa cells P<...5 and Ox HDL could promote the expression of Bax protein in granulosa cells P<...5 . Conclusion Ox HDL can inhibit the proliferation of rat granulosa cells induce apoptosis of granulosa cells and lead to the disorder of hormone secretion of granulosa cells.

KEY WORDS Oxidized high density lipoprotein Granulosa cells Hormone secretion

polycystic ovarian syndrome
PCOS m
ζ ε ● ش ل 6
ũ 1 j PCOS n "A "

TCGACTCATCACTGCACTC 3v ; 5 ū CT
 GACTGCATGCACTGC 3 ū PCR

Ė⁵ w GAPDH Ė ε Ĩ Ъ 2^{ct}
 Ė Ъ

1.5 Western blot Ė H w ѡ
 Ė

24 h~ RIPA
 Ъ BCA
 Ъ 1. % SDS PAGE Ů⁶
 Ů P T D F^τ 5%


1 h~ Ů Ů Bcl 2 e
 StAR αFSHR αStAR π 4 Ÿ
 Ė HRP J 1.5 h ECL 'H
 ~ ImageJ Θ Ů e Ъ

1.6 Ů
 SPSS 19.. Θ Ů Ъ
 w $\bar{x} \pm s$ Ъ t P<...5
 τ Ъ

2

2.1 Ox HDL PCOS ѡ Ů
 Ĩ

PCOS Ox HDL Θ ~
 ѡ ; 'H ѡ
 H H e ~ τ P<
 ...5 Ъ 1 Ъ



Bcl 2 Ė ѡ 5 ū
 CTGCACTGCACGTCTGCAC 3 ū ; 5 ū CGT
 CACTGCAGTGCTCA 3 ū Bax Ė ѡ 5 ū
 CTGCTCACTCACTGCACTC 3 ū ; 5 ū TC
 GACTGCACTCCTAC 3 ū FSHR Ė ѡ
 5 ū CGTGCCTGCACTGCATGCCATC 3 ū ; 5 ū CTA
 ACTGCGTCACTC 3 ū StAR Ė ѡ 5 ū

2.2 Ox HDL PCOS ѡ Ĩ
 ' hematoxylin eosin
 HE ѡ ѡ I 4 ѡ
 "Ω ѡ Ъ

2.5 Ox HDL ǎ H ʘ ů

ǎ ǐ

Western blotting ǎ ǎ Ox HDL ’

ǎ Bcl 2 ǎFSHR ǎStAR P<

...5 Ox HDL ’ Bax ǎ mRNA P<

τ P<...5 ǎ 4 ǎ

...5 Ox HDL ’ Bax ǎ mRNA P<

P<...5 ǎ 5 ǎ

3

PCOS í ǎ ů

3	IGF 1	6	TEGF C1	TEGFR3	A	Ä	n %	$\bar{x} \pm s$
R_`jc 1	Pcj_rgm lsfgn `cruccl scpsk GED U / jc t cj cxnpccssgm l s md T CED U A _lb T CEDPI U gl rgssscs _lb n_rfmjmega_j	dc_rspcs gl amjml a_lacp epmsn	n %	$\bar{x} \pm s$				
	n	IGF 1 ng/mL	P e	TEGF C	P e	TEGFR3	P e	
	36	145.26 $\pm$ 5.64	..4.5	23 63.69	..665	22 61.11	..593	
	24	143.93 $\pm$ 4..5		14 56.33		13 54.15		
	15	144.26 $\pm$ 3..4	..5.6	9 6....	..656	9 6....	..66.	
	45	146.63 $\pm$ 6.22		26 62.22		26 55.56		
	23	139.54 $\pm$ 4.69		13 56.52	..516	11 45.63	..193	
	35	156.32 $\pm$ 6.21		24 64.66		24 64.66		
	49	136.93 $\pm$ 5.66	2	25 55.1.	...25	25 55.1.	..264	
	11	155.52 $\pm$ 3.45		1. 9...1		6 52.52		
	41	132..5 $\pm$ 5.34		21 51.22	...14	2. 46.56	...25	
	19	156.2. $\pm$ 3.94		16 64.21		15 56.95		
	35	156.53 $\pm$ 5.96		26 55.66	...5	26 5..25	...15	
	23	133.29 $\pm$ 4.31		9 39.13		9 39.13		

UGT1A1

UGT1A1 gene polymorphism in different ethnic groups in Wunnan Province during infancy. Methods A total of 65 infants with GS and CNS diagnosed in the neonatal and digestive medicine clinics of our hospital from January 2016 to November 2019 in the border areas of Nujiang Baoshan Lincang and Diding Wunnan were collected. Observation group genetic tests were positive and 65 healthy

Qrsbw m l rfc Nm jw kmpnfgq k md UGT1A1 Ec lc gl Slam lhse_rcb Fwn cp`ggjps`g I lckg_md Bgddcpclr L_rgm l_jgrgcq gl Wsll_l Npmtglac bspgle Gld_law I SG Jg wsc U?LE Kglewgle XFMS @_gggle JG Jg FC Vg_mjg QFG Qfsj_l QFCL Ps Bcn_prkclr md ajglga_j_j`mp_rmpw l sl kgle Afjgl Bcl fmqng_r_j l sl kgle Wsll_l Afgl_34....

?@QRP?AR M`hcartc Rm qrsbw rfc Slam lhse\_rcb fwn cp`ggjps`g lckg_md UGT1A1 gene polymorphism in different ethnic groups in Wunnan Province during infancy. Methods A total of 65 infants with GS and CNS diagnosed in the neonatal and digestive medicine clinics of our hospital from January 2016 to November 2019 in the border areas of Nujiang Baoshan Lincang and Diding Wunnan were collected. Observation group genetic tests were positive and 65 healthy

P<...5 . Han children with c.211G>A c.1456T>G c.1.61C>T heterozygous mutations were higher than those of ethnic minorities χ^2 test "A" $P=0.001$ g 1456C>T $P=0.001$

1
Table 1 Primer design

UGT1A1		Ω 5 ũ3 ũ	bp	↳				
Ė								
Exon 1	~	GACACAGTCAAACATTAACCTTGGT	1 125	95 Ÿ 2 min	94 Ÿ 3. s	56 Ÿ 3. s	52 Ÿ 4. s	35
	κ~	TGATGCCAAAGACAGACTCAAAC						
Exon 2	~	GGAAGTAAAGGAGAGGAAAATGC	463	95 Ÿ 2 min	94 Ÿ 3. s	56 Ÿ 3. s	52 Ÿ 4. s	35
	κ~	AACAATGACAACAACCACAACAA						
Exon 3/4	~	AAGTTGCCAGTCCTCAGAAGC	651	95 Ÿ 2 min	94 Ÿ 3. s	56 Ÿ 3. s	52 Ÿ 4. s	35
	κ~	TTTGAACAACGCTATTAAATGCT						
Exon 5	~	AGGCAGGAGGATGGCTTG	553	95 Ÿ 2 min	94 Ÿ 3. s	56 Ÿ 3. s	52 Ÿ 4. s	35
	κ~	GGGGGCACGATACATATTCA						

1 Alamut	Θ	ñ 3 Y A	‘
	Ä	↳ H	ũ ä 1 “
x ± s	Θ	t	n
%	Θ		
P < ... 5 ε		τ ↓	
2			
2.1	≡ m		
	≡	Θ	Θ ũ ũ
	Θ	Θ	Θ κ
	τ	P > ... 5 ↓	Ė ‘ ↓ 2 ↓
	2	≡	í

Table 2 Comparison of clinical data between the 2 groups

	n=65	n=65	t/	P e
& ‘	12.66 88.1	12.51 82.95		.542
Ÿ	36.54 8.65	36.6. 8.51		.616
Ÿ l kg	3.21 8.26	3.26 8.3.		.3.5
ä / [	35/3.	32/35		.365
g/L	126.44 812.23	13...4 81.13		.411
Ä. %/L	6.55 81.1	6.43 8.96		.462
τ Ė				
† τ Ė	35 55.22	35 52.24		
μ † †	22 32.64	2. 29.65		.622
‘ τ Ė	6 11.94	12 15.91		
	35 55.22	4. 59.5.		.6..
	3. 44.56	25 4..3.		
C κ				
mg/L	.96 8.11	1..1 8.13		.152

2.2	≡	UGT1A1	ġ	↳ H	ġ	A	H
ġ		ũ					
		UGTIAI ä		HGMD			

c.211G>A	5 “	c.1456T>G	3 “
c.1.61C>T	≡	↳ H	ġ
ũ	‘	Hardy Weinberg	P > ... 5 Ė ж
μ		c.211G>A	ä.1456T>G
T H	↳	H	P < ... 5
1	H	ġ	Ė
... 5 ↓	3 ↓		τ P <
3	UGT1A1	ġ	↳ H
		ġ	A
		H	ġ
		n %	ũ

Table 3 Genotype and allele frequency distribution of UGT1A1 mutation site n %

	n=65	n=65	P e
c.211G>A			
GG	25 35.31	55 65.54	
‘ ↳ GA	3. 44.56	1. 14.93	<...1
‘ ↳ AA	12 15.91		
↳	42 62.69	1. 14.93	
H ġ G	6. 59.5.	124 92.54	
H ġ A	54 4..3.	1. 5.46	<...1
c.1456T>G			
TT	25 35.31	65 95..1	
‘ ↳ TG	12 15.91	2 2.99	<...1
‘ ↳ GG	3. 44.56		
↳	42 62.69	2 2.99	
H ġ T	62 46.25	132 96.51	
H ġ G	52 53.53	2 1.49	<...1
c.1.61C>T			
CC	35 52.24	62 92.54	
‘ ↳ CT	3. 44.56	5 5.46	<...1
‘ ↳ TT	2 2.99		
↳	32 45.55	5 5.46	
H ġ C	1.. 54.63	129 96.25	
H ġ T	34 25.35	5 3.53	<...1

F@c?e

θ / Z⁰ J /p

٢ ϕ c D f c n _ r g r g q @ @ c ? l e r g e c l * à ñ
ℓ ñ ǒ τ ə í ə J F@c?e A
"A ʁ K w ʊ ʌ ? J R ʏ 'Y Ä J F@c?e '
ϕ J ɔ N C E ʊ ʁ D L ʏ L ? q Ψ F@c? ʁ
ʊ ' "A ɸ í ʈ "ʔ "A Y I ɔ
J ǒ F@c?e ʊ ɸ í y^m ε í ʈ ó
ɔ ɔ "A ɓ ɔ w ʔ J
Ψ ϕ c D Ä

?bt_lacq gl rfc os_l rgr_rgtc md qcpsk F@c?e_l b grq ajg lga_j qge lgdga_lac
AFCL Vgsjg XF?LE Vscbm!eB?G Cpfcg^p
/ , BgtgqgmI md Jgtcp Bgqc_qcRfc Dgdrf Fmqngr_j md Qfghg_xfs_le Fc`cg Kcbga\_j Slgtcpqgrw Fc`cg
Qfghg_xfs_le Afgl_ K ʘ ? , ʏ = E ʁ ! ? Vsqc_qc

0 . / 6 0 . / 6 / . 5 7
/ , . 3 . . 0 /
0 , 2 3 . . / 4
^p Cg k _bg_j@c f. 604 , a m k

1 ! UÂU'E

ψ

P=...16 J Zeng 16

HBeAg 'A IC

ŭ ű ɔ ŭ Ă Ă

ŭ ă ε ..3.4 1 ..351 P<...1 J Ė

HBeAg 'A K V Ă J

2.5 HBeAg ó HB T

Ψ τ

φ Ă ɔ ɐ HB T DNA ɐ

HBeAg φ H

HB T DNA ɐHBeAg 'A φ

∨ Ă J IT HBsAg 1 HBeAg

HB T DNA Hb 2... IU/mL IC

HBeAg Hb Hb IT ' Ă HBeAg

vs 15% P=...3 ↓

Shin²⁴ █ entecavir ETT 3

HBeAg/ HBe ε 31.5% ↓ Kuon

²⁵ HBeAg <36. PEIU/mL w w

12 HBeAg ; 1 log ' w 1

1 HBeAg/ HBe ↓

Ė NAs ψ HBeAg

3 HBeAg

ψ ; Hb Ė τ ↓

3 'A

HBeAg φ

HBT DNA

w HBeAg ' PEG IFN 1 NAs

ψ HBeAg H ' 'A

1 B ɔ ↓ ã ɔ H w x ũ

n ~ φ ɔ HBeAg

Ė Θ . ɔ

'A 'H B Ė í Θ ψ e

↓

A ğ

- 1 Gencay M Seddner A Pabinger S et al. Detection of in vi
vo hepatitis B virus surface antigen mutations: A comparison
of four routine screening assays J . J Tiral Hepat 2.16 25
1. 1132 1136.
- 2 Wursthorn K Zacher BJ

3 14 /

A ǎ

/ κ ὀ , ч 13 @
ϣ ψ Η,Ψ †

† 0. /0401 017ᵛ021,

0 J_knpnmnmsnjmq_QjBmnmsjmq R, Fc_pr d_gj spc ugr f
amknjcr cpcamtcpw gl _n_rgcᵛr ugr f qwqrckga jsnsq cpwrfck_
rmqH,qPcsk_r0n.j /331ᵛ27ᵛ30,

1 ὀ , ηζ Ω ж
LRn p m @ K N c K N M ĭ Η,Ψ † ´

0. //420. 02 / . ᵛ02 / 1,

2 1θ 1ᵛ r ,η x
Ψ Θ Η,ᵛ A 0. /64
/ 44ᵛ47,

3 R_leXWf_m?Vl rmgtα B_j, ?lrmglc BPcesj_rgml md
Nmqr rrp_lqj_rgml_j K n B s g d g l æ_ G k n s t c m d FKE@
Pcqn mH q 0 q r g m v g b P 0 b m 24 / Q g 4 e 0 l . ᵛj 1 2 ,

4 Afc l Ws QXf_m αr _j, Pm β e m 21 B R ᵛ P m v g
b_φ m _rfu_w gl n p m k m r g l e a c j j b c _r f r f p m s e f _s r m n f _e w
_l b d c p p m n r m q g q H s p @ g l m e a f f c _k p @ g d n g j w s p P c c q
Amk k s 0 l . /37/ 4 15ᵛ21,

5 ?kcp ga_l Amjjcec md P f c s k _r m j m e w , ?kcp ga_l a m j j c e c m d
p f c s k _r m j m e w e s g b c r j p g c l _c r q k b h h ᵛ g a p c c l g l e
_e c k c l r m d j s H s q ? p a r f p a g g g f a ᵛ n p c P c q
i c l 0 . /4024 575ᵛ6. 6,

6 Ks`_p_Li_kpg F, QQLa1P_NQqgdga_rgml md jsnsq
lcnfprggrkqqr m r _i c _j m m i m l r f ᵛ _a f g c t c k c l r q _l b j g k g r _
r g m l q m d r H c k l a d r c k p 0 n / 121 f n 5 ᵛ7. ,

7 Tgp_ F

[illegible]

```

/, ?lfsg Npmtglac l cw J`mp_rmpw md Rp_lqj_rgmI_j A_lacp Pcqc@cle`s Kcbga_j Amjjcec @cle`s
?lfsg Afgl_011... 0, Bcn_prkclr md @gmafcckgrrpw $ Kmjcasi_p @gmjm@cle`s Kcbga_j Amjjcec
@cle`s ?lfsg Afgl_011...

```

?@QRP?AR Cvmqm kccq_pc l_lmqc_jc tcqgajcq ugrf bq_kcrpcq mtl. V...lk amlr_ggle PL? jngnbq
_lb npmrcglq, Cvmqm kccq_pc nmjwctqgajcq dmp kcb `w glr acjjsj_p jwqmqm k_j n_prajc
_lb ì clcrqb ġ_r_i @_g_j rck ġ_g ^pmcltgmpl kclr, 3c@gle rfc nmac`q md rck r_i ^cj kclq

b I B . / 4 G B O Δ ж
 e v ` 0 X B 4 . 4 7 A ж~ ж 0 . / 5 F . 0 . / 6
 O Δ ж e v ` 0 5 B
 Θ π H / , ц Ъ 0 1 1 . . .
 0 , Ъ ц A ũ 0 1 1 . . .
 ρ м θ C g k w p j j k q k > a m k

3 / A=BPĐX Đ 0 ố qđ F1 Đ/r R8Phrb€E\ " < 3

[illegible]

